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ABSTRACT

THE ROLE OF ERK5 IN DOPAMINE NEURONAL SURVIVAL

By
Mayur S. Parmar
May 2014

Dissertation supervised by Jane E. Cavanaugh, Ph.D

The extracellular signal-regulated kinases (ERKs) 1, 2, and 5 play important
physiological roles in neurogenesis, neutrite outgrowth, and neuronal viability in the
central nervous system. In this study, ERK1, 2, and 5 expression and activation were
examined in the substantia nigra (SN), striatum (STR), and ventral tegmental area (VTA)
during postnatal development and normal aging using western blot analysis. An agerelated decrease in phosphorylated/activated ERK5 (p-ERK5) was observed in the SN
and STR, whereas an increase in total ERK1 was observed in all three regions. Higher
expression of total and phosphorylated ERK5 was observed at postnatal day zero (PND0)
in all dopaminergic regions, which declined with the postnatal development. However,
expression of total ERK1 and ERK2 increased with the postnatal development. An
increase in the p-ERK1 and p-ERK2 peak was observed in both dopaminergic cell bodies
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containing regions, SN and VTA at PND7 as compared to PND0. In contrast, no such
peak was observed in the STR with the postnatal development.
In primary DA cultures of the SN and VTA, inhibition of ERK5 but not ERK1
and ERK 2 activation significantly decreased DA neuronal viability. Pretreatment with
the glial cell line-derived neurotrophic factor (GDNF) or dopamine neuron stimulating
peptide-11 (DNSP-11) did not protect human dopaminergic SH-SY5Y cells against 6hydroxydopamine (6-OHDA)-induced toxicity at 24 h. However, GDNF or DNSP-11
pretreatment protected against 6-OHDA-induced increase in apoptotic signaling, as
measured by caspase-3/7 activity at 6 h; indicating that GDNF and DNSP-11 blocks
some, but not all, of the cytotoxic effects of 6-OHDA. Treatment of SH-SY5Y cells with
GDNF or DNSP-11 resulted in activation of ERK1, 2, and 5 signaling. Infusion of
DNSP-11 into the STR also resulted in modulation of ERK1, 2, and 5 signaling. Increase
in tyrosine hydroxylase expression was observed in the STR (42%) and SN (32%), at 7
days and 6 h, respectively, after DNSP-11 infusion.
Together, these data suggest the essential role of ERK1, 2, and 5 kinases in
dopamine neuronal survival, especially ERK5. These data raise the possibility that a
decline ERK5 signaling may play a role in age-related impairments in dopaminergic
function.
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Chapter 1: Introduction
1.1

Overview
In United States, people aged 65 years or older represents 12.8% (~39.2 million)

of the total population (US Census 2011). These data indicate that one in every eight
American is aged > 65 years. From 2010 to 2040, a large number of “baby boomers” is
projected to reach age 65; thus, by 2040, there will be approximately 79 million people
age 65 or older, a 21% rise from the current population.
As the population ages, an increase in the number of people suffering from
neurodegenerative diseases is expected to rise due to nervous system dysfunction. An
increase in the aging population is considered to be the biggest health challenge in terms
of occurrence of neurodegenerative diseases. Moreover, this rise in the aging population
will cost the U.S. economy billions of dollars each year, resulting from direct health costs
and an overall decline in work opportunities.
At the cellular and molecular level, alterations occurring with aging include an
accumulation of reactive oxygen species, a reduction in cellular antioxidant levels, and a
decline in mitochondrial function and pro-survival cellular signaling (Mariani et al.,
2005; Lin et al., 2006). Furthermore, clearance of misfolded proteins does not occur
effectively (Wang et al., 2006). The nervous system is particularly vulnerable to the
above mentioned deleterious age-related changes, which could result in the development
of neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD), and Amyotrophic lateral sclerosis (ALS) (Andersen, 2004; Mariani et al., 2005; Lin
et al., 2006; Wang et al., 2006). In these neurodegenerative diseases, both increased
neuronal function impairment and neuronal cell-death are observed. Over the next several
1

decades, the occurrence of neurodegenerative diseases is anticipated to rise due to
increasing life expectancies in industrialized nations resulting in a larger aged population.
With normal aging, a progressive loss of dopamine neurons is observed in the
substantia nigra (SN) of the brain. This neuronal loss results in dopaminergic nervous
system dysfunction, which makes a person more susceptible to developing PD.
Parkinson’s disease is the second most common neurodegenerative disease after AD. The
principle risk factor for PD is age, with incidence rising after age 60, peaking between
ages 85-89, and then declining after the age of 90 (Driver et al., 2009). PD affects more
than 1% of people over the age of 65 and 4% of the population is afflicted by the age of
85 years. Clinically, PD is defined by the presence of the following motor signs:
bradykinesia, rigidity, tremor, and postural instability (Burke and O'Malley, 2012). These
motor declines are associated with the loss of the dopamine neurons in the SN and
reduced striatal dopamine neurotransmitter levels (Burke and O'Malley, 2012). Nonmotor features are also observed during the course of this disease, including cognitive
impairment, depression, insomnia, and anxiety (Chaudhuri et al., 2006). At the time of
PD symptom onset, the loss of dopamine neurons in the SN is ~ 30%, while the decline
in striatal dopamine levels is 50-60% as compared to age-matched controls (Burke and
O'Malley, 2012).
Numerous

studies

have

focused

on

understanding

the

dopaminergic

neuroprotective properties of neurotrophic factors, neurotrophins, and phytochemicals
against several neurotoxins (Spina et al., 1992; Fox et al., 2001; Guo et al., 2007) in order
to define therapeutic agents to halt progressive loss of DA neurons in PD. However, our
understanding of the cellular and molecular mechanisms underlying the basal survival of
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dopamine neurons is not clear. Moreover, the changes in expression and activation of
signaling pathways during postnatal development of dopaminergic neurons and normal
aging have been not observed. In this study, an effort was made to elucidate the agerelated cellular signaling changes, specifically mitogen activated protein kinases
(MAPKs), in the dopaminergic system, which includes the substantia nigra, ventral
tegmental area, and striatum. The role of mitogen activated protein kinases (MAPKs),
namely, the extracellular signal-regulated kinases (ERK) 1, 2, and 5 were studied. These
signaling pathways are known to protect dopamine neurons against neurotoxins (Ugarte
et al., 2003; Cavanaugh, 2004; Lindgren et al, 2008). The cellular role of these signaling
pathways in the basal survival of dopamine neurons were investigated by blocking their
activation/phosphorylation.
Glial cell line-derived neurotrophic factor (GDNF) and dopamine neuron
stimulating peptide-11 (DNSP-11) have been shown to be important for the basal survival
of dopamine neurons in vitro (Lin et al., 1993; Bradley et al., 2010) and for protection
against neurotoxins both in vitro and in vivo (Fox et al, 2001; Bradley et al., 2010; Sonne,
2013).

However,

the

cellular

and

molecular

mechanisms

underlying

these

neuroprotective properties are not clear. Hence, this research aimed to understand the
cellular signaling pathways that are activated by GDNF or DNSP-11 in vitro and in vivo.
Also, it was tested whether GDNF or DNSP-11 protects human dopaminergic SH-SY5Y
cells against 6-hydrodopamine (6-OHDA)-induced toxicity. Overall, the goal of this
dissertation project is to understand the cellular signaling pathways that are important for
basal dopaminergic neuronal survival, and elucidate whether activation of these signaling
pathways is crucial for therapeutic agent-mediated dopaminergic protection.
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1.2

The dopamine system

1.2.1 Dopamine
Dopamine (DA) is the neurotransmitter that plays a crucial role in regulating
motor coordination (DeLong, 1990; Graybiel et al., 1994), learning and memory
(Kulisevsky, 2000), and the sleep-wake cycle (Dzirasa et al., 2006). Dysfunctioning of
the dopamine system is known to be associated with numerous psychiatric and
neurodegenerative disorders, including schizophrenia, and Parkinson’s disease (PD).
1.2.1.1 Dopamine Synthesis, Release, Uptake, and Metabolism
Dopamine is a catecholamine synthesized from the amino acid precursor tyrosine.
Tyrosine is a non-essential amino acid that is taken up through the blood-brain barrier by
a transporter into the dopaminergic neurons. DA is then synthesized in a two-step process
(Fig. 1). In the cytoplasm of a DA neuron, tyrosine is converted into L-3, 4dihydroxyphenylalanine (L-DOPA) through an enzymatic reaction with tyrosine
hydroxylase (TH), the rate limiting enzyme in DA synthesis. L-DOPA is then converted
into cytosolic DA by aromatic amino acid decarboxylase (AADC). The activity of TH is
regulated by phosphorylation of 3 sites (ser19, ser31, ser40). The amount of DA
synthesized is dependent on the modulation of TH activity. Once DA is synthesized, it is
transported into the synaptic vesicles by the vesicular monoamine transporter 2
(VMAT2). Hence, the cytosolic DA concentrations are normally quite low. Further, this
transport of DA into vesicles protects it from catabolizing enzymes. When an action
potential arrives at the axon terminal, the synaptic vesicles fuse with the plasma
membrane and release DA into the extracellular space between the presynaptic and
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postsynaptic neurons (the synaptic cleft) at a rate proportional to the firing rate of the
neuron.
Once DA is released from the presynaptic neuron, it is rapidly taken up from the
extracellular space by the DA transporters (DATs) that are present on the plasma
membrane of the presynaptic terminals. This uptake of DA by the DAT is important for
maintaining the homeostasis of extracellular DA. DA is also removed from the
extracellular space by uptake into glial cells and blood and diffusion out of the striatum.
The binding of DA to a presynaptic DA autoreceptor regulates DA synthesis by
modulating TH activity. It has been reported that an increase in extracellular DA can
result in inhibition of TH by 50%, while a reduction of extracellular DA levels leads to an
increase in DA synthesis by a factor of 4 to 5 (Best et al., 2009).
Inside dopaminergic neurons, DA is mainly catabolized by two successive
reactions (Fig. 1). First, monoamine oxidase (MAO-A) present in the cytosol transforms
DA into the corresponding aldehyde, which then acts as a substrate for aldehyde
dehydrogenase to produce 3,4-dihydroxyphenylacetic acid (DOPAC). The metabolite
DOPAC diffuses out of the neuron into the synaptic cleft, where it is either conjugated
with glucuronides or metabolized to 3-methoxytyramine (3-MT) by catechol-Omethyltransferase (COMT) that is only present outside dopaminergic neurons. This 3-MT
is then oxidized by MAO-B, which is present in non-neuronal cells such as astrocytes and
glia (Mallajosyula et al., 2008), to form HVA.

5

Figure 1: The pathway of dopamine synthesis, release, uptake, and metabolism
TH-Tyrosine hyroxylase; AADC-aromatic amino acid decarboxylase; L-DOPA-L-3, 4dihydroxyphenylalanine; DA- dopamine; DAT- dopamine transporter;
MAO - monoamine oxidase; COMT-catechol-O-methyltransferase; DOPAC - 3, 4dihydroxyphenylacetic acid; HVA- homovanillic acid; 3-MT-3-methoxytyramine.

6

Since DOPAC results from newly synthesized DA through the activity of MAOA which is present inside the dopaminergic neuron, measurement of DOPAC levels
indicate the amount of DA synthesized. Overall, measurement of the turnover ratio of DA
metabolites [DOPAC/DA, HVA/DA, and (DOPAC+HVA)/DA] is indicative of the
activity of dopaminergic neurons. At the steady state in the brain, the measured
concentration of 3-MT is quite low due to the lower concentration of the extracellular DA
and fast interaction with the MAO-B to form HVA (Sotnikova et al., 2010). Previously,
several studies analyzed 3-MT as the indicator of DA release in various experimental
paradigms (Kehr, 1981); however, the use of in vivo microdialysis has established that
the measurement of 3-MT accumulation is an inaccurate measure of DA release (Vulto et
al., 1986; Elverfors et al., 1997; Sotnikova et al., 2010).
The physiological effects of DA are mediated by two main DA receptor subtypes,
namely D1- and D2. The D1-like receptors subtypes are D1 and D5, while the D2-like
receptors subtypes include D2, D3, and D4 (Jaber et al. 1997). These receptors are a
group of G-protein-coupled receptors (GPCRs) with 7 transmembrane domains. The D1type receptors are positively coupled to adenylyl cyclase and the D2-like receptors are
negatively coupled to adenylyl cyclase. The distribution of the DA receptors across the
dopaminergic system differs. The D1-like receptors are present in both dorsal and ventral
striatum, and are expressed mainly in the GABAergic medium-size spiny neurons
expressing substance P and dynorphin (Jaber et al., 1996). The D2-like receptors are also
expressed in the dorsal and ventral striatum, but they are expressed in the GABAergic
neurons expressing pre-proenkephalin (Jaber et al. 1996). Among all the DA receptor
subtypes, D1 and D2 are the most abundant subtypes in the CNS (Jaber et al., 1996)
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In the dopaminergic system, the three distinct nuclei that contain DA neuronal
cell bodies are the retrorubral field (RrF, A8), substantia nigra pars compacta (SNc, A9),
and the ventral tegmental area (VTA, A10) (Prakash and Wurst, 2006). The majority of
DA neurons reside in the SNc and VTA. The dopamine neurons in the SN and VTA are
distinct in terms of neurophysiological properties; vulnerability, protein expression, and
sensitivity towards neurotoxins (German et al., 1989; Ding et al., 2004; Korotkova et al.,
2005; Tagliaferro and Burke, 2010).
1.2.2 Basal Ganglia
In mammals, the basal ganglia consist of group of subcortical nuclei beneath the
cortex. Information from the cortices are channeled to the basal ganglia input nuclei [i.e.
striatum (caudate nucleus and putamen) and the subthalamic nucleus (STN)], and the
information is then relayed to the basal ganglia output nuclei [i.e. the substantia nigra
pars reticulata (SNr) and the internal globus pallidus (GPi in primates, GPm in rodents)].
The information from basal ganglia input to the output nuclei is relayed by the
GABAergic external globus pallidus (GPe in primates, GP in rodents) and glutamatergic
subthalamic nucleus (STh) (Hardman et al., 2002). The caudate, putamen, and nucleus
accumbens nuclei in the basal ganglia process information received from the central
nervous system, particularly the cortex. Within the basal ganglia are groups of neurons dopaminergic, γ-aminobutyric acid (GABA)-ergic, norepinephrine (NE), cholinergic, and
serotonin (5-HT) neurons. The input nucleus (i.e. the striatum) and the output nuclei (i.e.
the SNr) of the basal ganglia are widely studied across various mammalian species
(Hardman et al., 2002).
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Figure 2: Tyrosine hydroxylase (TH) immunostaining of dopamine neurons in the
substantia nigra (SN) and ventral tegmental area (VTA)
A) Twenty-five µm coronal rat brain section through midbrain was immunostained for
TH protein using primary TH (Millipore, Cat. No. MAB318, Mouse source, 1:1000)
antibody followed by detection using secondary infrared goat anti-mouse (Licor
biosciences, Cat. No. 926-32210, 1:10,000). Section was scanned on Odyssey scanner
(Licor Biosciences). B) Twenty-five µm coronal rat brain section through midbrain was
stained for TH protein using primary TH (Millipore, Cat. No. MAB318, Mouse source,
1:1000) antibody followed by detection using secondary goat anti-mouse (Invitrogen,
Alexa Fluor® 488, Cat. No. A-11001, 1:1,000) antibody. Section was scanned on EVOS
epifluorescent microscope (Model #AMF-4301-US, Advanced Microscopy Group).
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1.2.3

Substantia Nigra (SN)
The substantia nigra is divided into two main, distinct areas, called SN pars

compacta (SNc) and SN pars reticulata (SNr) (Fig. 2). The SNc contains densely packed
cell bodies of dopaminergic neurons of many shapes and sizes as compared to more
diffuse, triangular or round cell bodies in the SNr (Poirier et al., 1983; Robinson et al.,
2012) The SNr is comprised primarily of GABAergic neurons arranged in dorsoventrally
elongated clusters and they occupy DA-cell free regions (Gonzalez-Hernandez et al.,
2000; Robinson et al., 2012). Dopaminergic neurons arising from the SNc send their
projections to the dorsal striatum, particularly the caudate and putamen, forming the
nigrostriatal pathway. The nigrostriatal pathway controls voluntary movements and its
degeneration in humans leads to PD.

The dopaminergic neurons in the SNc are

modulated in terms of dopaminergic release and activation, through GABAergic input
from the SNr and feedback from the striatum. The loss of DA neurons in these regions
with age, or during neurodegenerative disease, disrupts basal ganglia circuitry resulting in
a loss of regulatory control of DA on to the GABAergic fibers, thereby, negatively
affecting motor coordination.
From a post-mortem brain study, it was found that the loss of DA neurons in the
SNc is up to 0.5 to 0.7 % annually (i.e. 5 – 7% per decade) (Seidler et al., 2010).
However, the age-related loss of DA neurons is controversial, such that some groups
have noted a significant decline in TH+ DA neurons with age (McGeer et al., 1977;
Fearnley and Lees, 1991; Emborg et al., 1998; Gerhardt et al., 2002), while others noted
no age-related decline in TH+ DA neurons (Wolf et al., 1991; Kubis et al., 2000). The DA
neurons in the SNc can be sub-classified into dorsal and ventral tier based upon the
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morphological features, neuronal projections, and patterns of protein expression (Gerfen
et al., 1987). The dorsal tier of the SNc contained a dense collection of DA neurons
(round or fusiform in shape) (Tagliaferro and Burke, 2010). These DA neurons project
dendrites mediolaterally and innervate the striatal matrix compartments (Gerfen et al.,
1987) and in turn receive input from the limbic patch compartment (Neuhoff et al., 2002).
These neurons are calcium-binding protein calbindin positive (CB+) and express low
levels of DAT (Neuhoff et al., 2002; Tagliaferro and Burke, 2010). While the ventral tier
of the SNc contained a sheet of densely packed angular cells of DA neurons (Gerfen et
al., 1987). The DA neurons of ventral tier SNc and SNr projects to the striatal patch
compartments and in turn receive information from striatal projection neurons in the
matrix (Neuhoff et al., 2002). The ventral tier neurons express aldehyde dehydrogenase
1A1 (ALHD1A1 or AHD2) and DAT (Tagliaferro and Burke, 2010). The DA neurons in
the ventral tier are more vulnerable to neurotoxin 6-hydroxyamine toxicity (Gerfen et al.,
1987) and are thought to be more vulnerable in neurodegenerative diseases such as PD
(German et al., 1989). This vulnerability difference is thought to be due to the higher
expression levels of calbindin in the SNc dorsal tier neurons.
1.2.4

Ventral Tegmental Area (VTA)
Dopaminergic neurons arising from the VTA send their projections to the ventral

striatum (Fig. 3), particularly the nucleus accumbens, olfactory tubercle, and other limbic
structures, such as amygdala and hippocampus, forming the mesolimbic pathway.
Dopaminergic neurons from the VTA also send projections to the cortical areas, such as
the medial prefrontal and entorhinal cortex, forming the mesocortical dopaminergic
pathway. In the VTA, a large network of GABAergic neurons is present, along with a
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small percentage of excitatory glutaminergic neurons. Dysfunction of this mesolimbic
pathway has been implicated in psychiatric disorders such as schizophrenia and drug
addiction. The DA neurons of VTA are less vulnerable or largely spared during
neurotoxicity or neurodegenerative diseases such as PD (German et al., 1989; Ding et al.,
2004; Di Salvio et al., 2010). Interestingly, the expression of calbindin is four times
higher in the VTA relative to the SN (Korotkova et al., 2005). It is thought that the higher
co-expression of this neuroprotective protein calbindin and transcription factors, such as
Pitx3, in the VTA as compared to the SN may contribute to the different vulnerability of
these dopaminergic neurons (Korotkova et al., 2005). Recently, Di Salvio et al. (2010)
reported that the presence of the transcription factor Otx2 in the VTA conferred
resistance to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-HCl (MPTP) toxicity.
Moreover, it has been suggested that the lower expression of DAT in the VTA as
compared to the SN also contributes to the lower vulnerability of the VTA to
neurotoxins.
1.2.5

Striatum (STR)
The striatum is the largest subcortical nuclei structure of the basal ganglia system

associated with motor planning, and motivation. It consists of the caudate nucleus and
putamen. In primates, the caudate nucleus and putamen are separated by the internal
capsule, while in rodents both regions are indistinguishable. In the rat, the striatum is
divided into two subdivisions: a dorsal striatum that contains most of the caudate and
putamen, and a ventral striatum, which contains the nucleus accumbens, as well as part of
the olfactory tubercle (Fig. 3). The primary dopaminergic input to the dorsal striatum
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arises from the SNc, while the primary dopaminergic input to the ventral striatum arises
from the VTA.
The striatum contains two distinct areas, called the striatal matrix and the striatal
patches.

These

areas

are

divided

based

on the

absence

or

presence

of

acetylcholinesterase. The striatal patch lacks acetylcholinesterase and thus has a high
concentration of acetylcholine. It is primarily innervated by limbic associated areas such
as the hippocampus. On other hand, the striatal matrix has a high concentration of
acetylcholinesterase and thus is a choline-rich environment. It is primarily innervated by
cortical and thalamic glutamatergic projections (Gerfen et al., 1992) Dopamine afferents
to the striatal matrix originate from the VTA, dorsal tier SNc, and retrorubral nucleus,
while dopamine afferents to the striatal patches arise from the ventral tier of the SNc and
the SNr.
The striatum contains multiple types of neurons, including GABAergic and
cholinergic neurons; however, it completely lacks glutamatergic neurons (Kreitzer et al.,
2008). The principal cell type in all the striatal regions is the GABAergic medium spiny
neurons which constitute > 90% of all neurons in the striatum (Gerfen, 2004). These
GABAergic medium spiny neurons are characterized by high spine density, negative
resting potential, and low firing rates in vivo (Kreitzer et al., 2008). Regulation of DA
signaling in the striatum through GABAergic interneurons, along with the rest of basal
ganglia, plays a crucial role in controlling motor coordination.
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Figure 3: Tyrosine hydroxylase (TH, green) and dopamine transporter (DAT, red)
immunostaining of dopamine projections in the striatum
Twenty-five µm coronal rat brain section through striatum was immunostained for TH
(green) and DAT (red) protein using primary TH (Millipore, Cat. No. MAB318, Mouse
source, 1:1000) and DAT (Millipore, Cat. No. MAB369, Rabbit source, 1:1000)
antibodies followed by detection using secondary infrared antibodies, goat anti-rabbit 680
(Licor biosciences, Cat. No. 926-68021, 1:10,000) and goat anti-mouse (Licor
biosciences, Cat. No. 926-32210, 1:10,000), respectively. Section was scanned on
Odyssey scanner (Licor Biosciences). Sections prepared and stained by Mayur S. Parmar.
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1.3

Development of dopaminergic system
Midbrain dopaminergic (mDA) neurons are the main source of DA in the

mammalian central nervous system and are located in three distinct nuclei: the ventral
tegmental area (VTA), the substantia nigra pars compacta (SNc), and the retrorubral field
(RrF; Prakash and Wurst, 2006). Cells of the SNc are involved in the control of voluntary
movements and postural reflexes, and their degeneration in the adult brain has been
associated with the development of Parkinson’s disease (PD; Fearnley and Lees, 1991;
Anglade et al., 1997). Dopamine cells of the VTA modulate rewarding and cognitive
behaviors, and dysregulation of DA transmission in the mesolimbic system has been
implicated in the pathogenesis of addictive disorders (Kelley and Berridge, 2002;
Wightman and Robinson, 2002), depression (Dailly et al., 2004), and the psychotic
symptoms of schizophrenia (Carlsson et al., 2001; Sesack and Carr, 2002).
During prenatal development, DA neurons are induced in the ventral midbrain by
an interaction between two diffusible factors: sonic hedgehog (Shh) and fibroblast growth
factor 8 (Fgf8; Simon et al., 2003). In mice, the first postmitotic differentiating DA
neuron appears at embryonic day 10-10.5 (E10-10.5) during CNS development. By
E11.5, the first specific sign of developing midbrain DA neurons, indicated by an
increase in tyrosine hydroxylase (TH) expression, is observed (Foster et al., 1988; Wallen
et al., 1999). The neurons of the SNc and RrF are generated first between E10 and E13
(peaking at E11 and E12), whereas the neurons of the VTA are generated approximately
1 day later, between E10 and E14 (peaking at E12 and E13) (Prakash and Wurst, 2006).
Once DA neurons are generated, several transcription factors, which are crucial for
postmitotic DA cell development, such as Nurr1, Lmx1b, Pitx3, and En1/En2, are
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induced (Wallen and Perlmann, 2003). During prenatal development, DA neurons
undergo generation, specification, and migration to their final positions. Midbrain VTA
and SN neurons project via the medial forebrain bundle (MFB), arriving in the ventral
and lateral regions of the rat STR at E14 and in the remaining areas of the STR by E18
(Sillivan and Konradi, 2011). By E20, DA neurons assume topography similar to that of
the adult brain (Shults et al., 1990).
Following embryonic mitosis, specification, and migration, the events that occur
during postnatal development of the dopaminergic system include establishment of
contact and interaction between the SN and other neural nuclei; these developmental
events occur through the extension of axons, terminal differentiation, and synaptic
formation. A rapid increase in synaptic formation in the STR is observed between PND13
and PND17 (Hattori and McGeer 1973), while postnatal differentiation of DA terminals
is indicated by a large increase in STR TH activity and DA uptake between birth and
PND30 (Coyle et al., 1977). A large increase in synapse formation is also observed in the
SNc between PND15 and PND30. Interestingly, a natural DA cell death event that is
apoptotic and biphasic in nature is observed during postnatal development and is a
common feature in mammals (Janec and Burke 1993; Oo and Burke 1997; Jackson-Lewis
et al. 2000; Burke, 2003; Burke, 2004). For example, in rats, natural cell death (NCD) of
DA neurons in the SNc begins shortly before birth and initially peaks on PND2 with a
second, smaller peak at PND14 (Burke, 2003). By PND20, the event has largely abated
(Burke, 2003). A natural cell death event is also observed in the STR between PND4 and
8 (Fentress et al., 1981).
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The sequence of events and the relative duration of mDA neuron development are
conserved between mice and rats, taking into consideration that mouse development
precedes that of rats by approximately 1 to 2 days (Prakash and Wurst, 2006). By the
third postnatal week, the aspect of mDA neuron development (maturation of the mDA
system) appears to be finished and the mDA system has acquired its adult morphology
and functionality (Prakash and Wurst, 2006). These early brain development events
ultimately determine brain function throughout life.
1.3.1 Modulation of cellular signaling during development of the dopaminergic
system
Despite considerable progress in our understanding of the postnatal development
of DA neurons in the vertebrate brain, including the determination of neuron number,
axon guidance, target contact, and natural cell death events (Janec and Burke 1993; Oo
and Burke 1997), cell signaling cascades within mesencephalic dopamine neurons that
might alter and control these processes are not well studied and much remains to be
elucidated. During early postnatal development of the dopaminergic system, any event
that may alter the cellular signaling pathways required for normal growth could
predispose an adult to the risk of developing neurodegenerative and neuropsychiatric
disorders early or later in life, and/or alter the normal age-related changes in the
dopaminergic system. Research has indicated that neurotoxin exposure during early brain
development (prenatal or postnatal) has a profound, deleterious effect on the developing
and adult nigrostriatal and mesocorticolimbic systems and leads to enhanced neuronal
vulnerability, neurobehavioral impairments, and neurochemical alterations in the brain
(Ling et al., 2002, 2004, 2006, 2009; Cory-Slechta et al., 2005a, 2005b; Richardson et al.,
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2006; Zhu et al., 2007; Olczak et al., 2011), which persist into adult life. Studies have
also revealed that exposure to neurotoxins during development alter gene/protein
expression in the adult offspring (Richardson et al., 2006, Schneider et al., 2011). As the
dopaminergic system in the midbrain has been closely associated with serious
neurodegenerative and neuropsychiatric disorders, the elucidation of the signaling
mechanisms underlying dopaminergic neuronal development during the postnatal period
becomes crucial for the understanding the development of disease state.
1.4

Age-related changes in dopaminergic system

1.4.1

Nigrostriatal system
Advanced aging is associated with a progressive decline in motor functions due to

dysfunctioning and degeneration of the nigrostriatal dopaminergic system (Emborg et al.,
1998; Seidler et al., 2010). Several investigators have reported neurochemical,
neurophysiological, and cellular changes in the nigrostriatal dopaminergic system the
brains of rodents, non-human primates, and humans during normal and diseased aging.
With age, a reduction in the extracellular and tissue levels of DA in the SN and STR is
observed (Carlsson & Winblad, 1976; Irwin et al. 1994; Gerhardt et al. 1995, 2002; Fox
et al., 2001; Haycock et al., 2003). The age-related reduction of DA levels in the
nigrostriatal system is associated with the progressive loss of TH + DA neurons (McGeer
et al., 1977; Fearnley and Lees, 1991; Emborg et al., 1998; Gerhardt et al., 2002) and/or a
decrease in neuronal functioning due to a decline in TH mRNA, protein expression, and
activity (McGeer et al., 1977; Dickerson et al., 2009). In addition to the loss of TH
expression or activity, it has been reported that the loss of DA neurons in the SNc is
approximately 0.5 to 0.7 % annually (Seidler et al., 2010).
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Other normal age-related changes in the nigrostriatal system included the decline
in expression of membrane DAT (Allard and Marcusson, 1989; Salvatore et al., 2003;
Troiano et al., 2010), reductions in high affinity DA uptake sites (Zelnik et al., 1986; De
Keyser et al., 1990; Yue et al., 2012), reduction in striatal DA uptake (Salvatore et al.,
2003; Yue et al., 2012), and decreases in dopamine D1 and/or D2 receptors (Henry et al.,
1986; Rinne et al., 1990; Volkow et al., 1996, 1998). The decline in DAT and DAT
mRNA appears to be high in the SN (Bannon et al., 1992; Bannon and Whitty, 1997; Ma
et al., 1999) as compared to a stable or modest decline in the STR (Salvatore et al., 2003;
Haycock et al., 2003). The age-related decline in DA transmission, TH+ neurons, TH
expression, DAT, and DA receptors levels are strongly correlated with motor
impairments, such as decreased locomotion, involuntary jerking arm movements, gait
changes, and loss of balance during normal aging (Gerhardt et al., 1995, 2002; Emborg et
al., 1998; Volkow et al., 1998; Cham et al., 2007, 2008; Salvatore et al., 2009; Seidler et
al., 2010). However, a few groups have reported that there are no age-related changes in
DA levels, TH+ DA neurons or DAT and TH protein expression levels in the nigrostriatal
system (Wolf et al., 1991; Kubis et al., 2000; Salvatore et al., 2003; Allen et al., 2011).
This variability might be associated with the methods of investigation and the animal
strains used in the studies.
Decrease in the levels of the neurotrophic factor receptors, GDNF receptor GDNF
family receptor α-1 (GFRα-1) and the neuregulin receptor ErbB4, were observed in the
nigrostriatal system with normal aging (Dickerson et al., 2009; Pruett and Salvatore,
2010). Moreover, GDNF-mediated protection of DA neurons against 6-OHDA-induced
toxicity was significantly lower in older animals as compared to young animals (Fox et
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al., 2001).

These could be attributed to the lower levels of GFRα-1, resulting in

reduction in activation of prosurvival signaling by GDNF. Increase in oxidative stress
was also observed with aging in nigrostriatal system. A small, non-significant increase in
the number of 3NT+ (3-nitrotyrosine; a marker of nitrative damage) neurons in the
ventral SN was observed in old as compared to young animals (Kanaan et al., 2008).
However, a significant increase in the percentage of TH + neurons with 3NT was observed
with age (Kanaan et al., 2008). With age, the increase in 3NT +/TH+ neurons was higher in
ventral SN as compared to dorsal SN (Kanaan et al., 2008); a pattern indicating the
greater vulnerability of ventral SN as compared to dorsal SN in PD.
1.4.2 Mesoaccumbens system
Unlike the nigrostriatal system, less information about age-related changes in the
mesoaccumbens system (VTA and NAc) is available. Study by Siddiqi and colleagues
(1999) reported age-related loss of total neurons in the paranigral nuclei of the VTA of
the rhesus monkey. Salvatore and colleagues (2003) reported no age-related change in
DAT protein levels in VTA and NAc. However, a decrease in TH protein expression was
observed with age in the VTA (Salvatore et al., 2003). In contrast to TH protein levels, no
change in TH mRNA levels was observed with age in the VTA by Dickerson and
colleagues (2009). Contrary to reports of no change in DAT protein levels in the VTA
and NAc with age (Salvatore et al., 2003), a reduction in DAT ligand binding with aging
was observed in both VTA and NAc in the same rat strain by others (Hebert et al., 1999).
Moreover, a modest decline in the DAT immunofluorescence was observed with age in
the VTA (Kanaan et al., 2008). This indicates that the age-related change in cellular
localization of DAT might be important to study along with total DAT protein. Finally, a
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decrease in the ratio of DAT/VMAT was observed in the VTA with age, indicating
decreased capacity of DA neurons to accumulate cytosolic DA (Kanaan et al., 2008).
1.5

Neurotrophic and neuropeptide therapies for dysfunctional dopaminergic

system
Neurotrophic factors, such as brain derived neurotrophic factor (BDNF), glial
cell-derived neurotrophic factor (GDNF), and basic fibroblast growth factor (bFGF) have
been shown to promote dopaminergic system development through differentiation of DA
neuron precursors, maintaining DA neuronal viability and regulating early postnatal
developmental cell death of dopamine neurons of the SN (Hyman et al., 1991; Burke,
2003; Krieglstein, 2004; Oo et al, 2009). Moreover, these growth factors have been
shown to provide protection of dopaminergic neurons and dopaminergic cells against
neurotoxin-induced toxicity (Spina et al., 1992; Ugarte et al., 2003; Li et al., 2013; Hsuan
et al., 2006).
Among these growth factors, the high potency of GDNF in promoting dopamine
neuronal survival, regeneration, and neuritic outgrowth (Lin et al., 1993; Zawada et al.,
1996; Deierborg et al., 2008) has made it the most widely studied neurotrophic factor as a
therapeutic agent to treat neurodegenerative diseases, such as PD.
1.5.1 Glial cell line-derived neurotrophic factor (GDNF)
GDNF, a member of the transforming growth factor-β superfamily, was originally
purified in 1993 from the rat glioma cell-line (B49) as a trophic factor that prompted the
survival of embryonic dopaminergic neurons (Lin et al., 1993). At this time Lin and
colleagues also noted that GDNF promotes dopamine uptake and increases TH + DA
neuron survival in midbrain cultures (Lin et al., 1993). In these cultures, GDNF affects
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neither the density of astrocytes nor the expression of glial fibrillary acidic protein
(GFAP), indicating its specificity and potency towards DA neurons (Lin et al., 1993).
These effects of GDNF have also been confirmed in intact adult animals (Hudson et al.,
1995). A single intracranial, unilateral infusion of GDNF into the SN leads to a dosedependent and persistent increase in TH activity, DA levels, and DA turnover, both in the
SN and STR (Hudson et al., 1995). No effect of GDNF infusion was observed on
norepinephrine or serotonin levels (Hudson et al., 1995). In the same animals, increases
in motor activity were observed following GDNF treatment (Hudson et al., 1995). In the
STR, potassium and d-amphetamine-evoked DA release was increased in animals treated
with GDNF (Hebert and Gerhardt, 1997). These promising effects of GDNF prompted
studies to evaluate the ability of GDNF to protect dopamine neurons in vivo and in vitro
against neurotoxins including MPTP, 6-OHDA, rotenone, and paraquat, all of which are
known to induce specific DA neuronal loss.
Using in vitro (Hou et al., 1996; Ugarte et al., 2003; Ding et al., 2004; Hsuan et
al., 2006; Li et al, 2013) and in vivo rodent models (Hoffer et al., 1994; Kearns and Gash,
1995; Connor et al., 2001, Fox et al., 2001) of dopaminergic dysfunction, several studies
have demonstrated the potential of GDNF to protect DA neurons or dopaminergic cells
against toxic insults and to enhance and/or partially restore dopaminergic neuronal
function. In normal and parkinsonian, non-human primate models, GDNF treatment has
led to significant improvements in neurochemical and behavioral function (Gash et al.,
1995, 1996; Zhang et al., 1997; Grondin et al., 2002). Improvements in neurochemical
functions include an increase in DA and HVA levels in the nigrostriatal and
mesoaccumbens pathways. Behavioral functions that improved following GDNF
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treatment include alleviation in parkinsonism features, such as bradykinesia, rigidity,
poor posture, and impaired balance. In the dopaminergic dysfunction/parkinsonian nonhuman primate model, restoration of the nigrostriatal dopaminergic system and increases
in both TH+ dopamine neurons and TH+ fiber density were also noted (Gash et al., 1995,
1996, 2005; Grondin et al., 2002).
Promising therapeutic results in the dopaminergic dysfunction/parkinsonian
rodent and non-human primate model resulted in consideration of GDNF for clinical trial.
In two different phase I clinical trials, GDNF therapy showed positive behavioral results
including: 1) a 39% improvement in the off-medication motor score of the Unified
Parkinson's Disease Rating Scale (UPDRS), 2) a 61% improvement in the activities of
daily living score, 3) a 34% and 33% increase in total UPDRS score in “on” and “off”
states, respectively, as compared to baseline after 24 weeks, 4) a 28% increase in
putamen dopamine storage after 18 months of GDNF delivery, 5) improved balance and
gait and increased speed of hand movements, which continued through the washout
period, and 6) an improvement in fine motor control (Gill et al., 2003; Slevin et al.,
2005). However, in phase II, all clinical trials with GDNF were discontinued due to a
lack of positive clinical results, detection of antibodies against GDNF in 10% of the
patients undergoing trial, and observations of unusual cerebellar cortical pathology in
non-human primates (Nutt et al., 2003; Land et al., 2006; Hovland et al., 2007). It is
believed that technical differences in drug-delivery, thereby affecting distribution of
GDNF, and inter-trial variability between both phases led to the discrepancies between
results (Salvatore et al., 2006).

Due to the beneficial effects of GDNF on the

dopaminergic system, as noted in rodents, non-human primates, and humans (phase I
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clinical trial), numerous ongoing studies are focused on understanding the
neuroprotective molecular mechanisms of GDNF. Studies are also focused on examining
different GDNF formulations (Shingo et al., 2002) or routes of administration in order to
avoid the issues raised during clinical trials. Despite the setbacks, GDNF remains a
promising neurotrophic factor to halt the loss of dopamine neurons and restore normal
dopaminergic system function in PD.
1.5.1.1 Molecular mechanism of GDNF action
GDNF signals through binding to its co-receptor complex, which consists of the
GDNF family receptor, GFRα-1, and the membrane receptor, RET protein tyrosine
kinase (RET). The mRNA and protein for these receptor components are present within
the nigrostriatal and messoaccumbens pathways (Trupp et al., 1996; Golden et al., 1999;
Smith et al., 2003; Pruett and Salvatore, 2010). Upon binding to its receptor complex,
GDNF activates the PI-3K/Akt and mitogen-activated protein kinase (MAPKs) signal
transduction pathways (Worby et al., 1996; Lindgren et al., 2008; Li et al., 2013).
Activation of these signaling pathways by GDNF is known to protect dopaminergic
MN9D cells against 6-OHDA-induced toxicity (Ugarte et al., 2003; Li et al., 2013).
Protection of dopaminergic cells with GDNF is also mediated through activation of the
NF-κB signaling pathway (Cao et al., 2008, 2013). GDNF-mediated upregulation of the
anti-apoptotic proteins, Bcl (B-cell lymphoma) -2 and Bcl-w, and downregulation of the
pro-apoptotic proteins, Bax and Bad, also resulted in MN9D cell protection against 6OHDA toxicity (Cao et al., 2013). Similarly, a study by Li et al. (2013) reported that
GDNF-mediated

upregulation

of

apoptosis-inhibiting
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genes

(e.g.

Ager),

and

downregulation of apoptosis-promoting genes (e.g. Ccnl2) resulted in protection against
6-OHDA toxicity in MN9D cells.
1.5.2

Dopamine Neuron Stimulating Peptide-11 (DNSP-11)
Due to CNS delivery issues with GDNF therapy, the search began for a small

molecule that has potent neurotrophic effects, similar to GDNF, in terms of protecting the
dopaminergic system and that can be easily delivered through alternative routes.
Recently, a study by Bradley and colleagues (2010), reported an 11-mer peptide from the
pro-GDNF domain called Dopamine Neuron Stimulating Peptide-11 (DNSP-11); in
dopamine neurons, DNSP-11 displays both neurotropic and neuroprotective effects
similar to GDNF (Fuqua, 2010; Sonne, 2013). Most importantly, they were able to
deliver DNSP-11 through non-invasive intranasal administration and shown that it
protects dopamine neurons against neurotoxin-mediated loss of dopamine neurons
(Sonne et al., 2013). This indicates easy delivery of DNSP-11, thereby, presumably
avoiding issues related to CNS route of administration.
In vivo expression of DNSP-11 in rats was observed in the SN and VTA, and colocalization of DNSP-11 was observed with TH + DA neurons (Bradley et al., 2010).
Further, when exogenous DNSP-11 was infused into the SN, it was rapidly and
specifically taken up by the TH+ DA neurons (Bradley et al., 2010). Immunostaining for
DNSP-11 also suggested its presence in other brain regions, such as the locus coeruleus
(LC), glomeruli of the olfactory bulb, and dentate gyrus and CA1-CA3 regions of the
hippocampus (Sonne, 2013). When dual-fluorescence immunohistochemistry was
applied, colocalization of DNSP-11 and GDNF were observed in the adult facila motor
nucleus, STR, cerebellum, and medial lemniscus (Sonne, 2013). Differences in the
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localization of DNSP-11 and GDNF have also been observed in the SN, VTA, and LC
regions

(Sonne,

2013).

Another

important

difference

observed

using

immunohistochemistry was the presence of DNSP-11 during both postnatal development
and adulthood in the SN, while GDNF was present only during postnatal development
but dissipated in adulthood (Sonne, 2013). The expression differences of DNSP-11 and
GDNF in various brain regions suggests that DNSP-11 and GDNF may be undergoing
different post-translation modifications or may have different half-lives (Sonne, 2013).
In an in vitro study of primary mesencephalic cells, DNSP-11 treatment increased
cell survival comparable to results obtained following GDNF exposure (Bradley et al.,
2010). DNSP-11 treatment produced similar effects as GDNF treatment in enhancing
morphological changes, such as neurite length and total branch number per neuron.
Moreover, both DNSP-11 and GDNF treatment led to an increase in the total number of
TH+ cells (Bradley et al., 2010). Also comparable to GDNF, DNSP-11 pretreatment
reduced a 6-OHDA-induced increase in TUNEL positive staining, caspase-3 activity in
the MN9D dopaminergic cell line (Bradley et al., 2010). DNSP-11 treatment also
protected dopaminergic cell lines (MN9D and B65) against several other neurotoxins,
such as rotenone and MPP+ (Bradley et al., 2013). Interestingly, unlike GDNF, DNSP-11
protected the B65 cell line against staurosporine and gramicidin toxicity (Bradley et al.,
2010), suggesting a difference in the mechanisms of cellular protection. DNSP-11 has
also been shown to protect cells against toxin-induced loss of mitochondrial membrane
potential (Kelps et al., 2011; Bradley et al., 2013), indicating its mitochondrial-protective
properties. DNSP-11 pretreatment blocked toxin-induced cytochrome c release from
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mitochondria (Bradley et al., 2013) suggesting DNSP-11 may exploit apoptotic
mechanisms at several points in the apoptotic pathway.
In animal models, DNSP-11 appears to be comparable to GDNF in terms of its
neuroprotective effect on the dopaminergic system. Infusion of DNSP-11 in the SN of
normal rats resulted in an increase in baseline concentrations of DA and its metabolites,
DOPAC and HVA, in the STR (Bradley et al., 2010). Intranasal delivery of DNSP-11 in
normal rats significantly increased DA turnover [(DOPAC+HVA)/DA] in the STR and
SN, and DA metabolites (DOPAC and HVA) in the SN (Sonne, 2013). In a rat model,
one week after the induction of a 6-OHDA-induced lesion, post-infusion of DNSP-11
reduced apomorphine-induced rotation behavior and increased DA and DOPAC levels in
the SN (Bradley et al., 2010). Promising results were also observed with intranasal
delivery of DNSP-11 in rats following 6-OHDA-induced lesions (Sonne, 2013). The
beneficial neuroprotective properties of DNSP-11, combined with the ease of its
intranasal delivery, make it a promising therapeutic agent to treat the dysfunctional
dopaminergic system in PD.
1.5.2.1 Molecular mechanism of DNSP-11 action
Unlike GDNF, the neuroprotective molecular mechanisms of DNSP-11 are not
well-established. However, similar to GDNF, DNSP-11 has been shown to activate
ERK1 and ERK2 signaling (Bradley et al., 2013). However, it has not yet been elucidated
whether DNSP-11-mediated activation of ERK1 and ERK2 or ERK5 are responsible for
its neuroprotective properties. MALDI-TOF mass spectroscopy indicated 16 cytosolic
proteins pull-down by DNSP-11, out of which 11 possesses metabolic functions that
includes a neuroprotective drug target, glyceraldehyde 3 Phosphate Dehydrogenase
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(Bradley et al., 2010). This indicates that DNSP-11 might have neuroprotective properties
due to its interaction with cytosolic proteins.
1.6

Mitogen-activated protein kinase (MAPK) signaling
Mitogen-activate protein kinases (MAPKs) are highly conserved enzymes that are

involved in a multitude of cellular functions such as cell proliferation, differentiation,
survival, and apoptosis (Cobb, 1999; Qi and Elion, 2005; Zhuang and Schnellmann,
2006). Each MAPK cascade consists of a three-tier kinase cascade: a MAP kinase kinase
kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK, MAP2K, or MEK), and
a MAP kinase (MAPK). Sequential activation of MAPK kinases occur in response to
either extracellular stimulation by growth factors or environmental stresses, finally
resulting in MAPK phosphorylation. Specific downstream effector molecules
(transcription factors, structural proteins, and cytoplasmic enzymes) are activated through
sequential activation of each component of the MAPK cascade (Fig. 4) (Yang et al.,
2003; Qi and Elion, 2005; Yoon and Seger, 2006).
MAPKs are activated by dual phosphorylation of conserved threonine and
tyrosine residues within the activation loop of the kinase (denoted T-X-Y) and the MAPK
targets contain a Pro-Xxx-Ser/Thr-Pro sequence (Ferrell and Bhatt, 1997; Pearson et al.,
2001; Qi and Elion, 2005; Nithianandarajah et al., 2012). Once activated, MAPKs can
translocate from the cytoplasm to the nucleus to phosphorylate nuclear targets, and once
dephosphorylated they translocate from the nucleus back to the cytoplasm (Kondoh et al.,
2006; Nithianandarajah et al., 2012). The activated MAPKs can remain in the cytoplasm
and activate cytoplasmic proteins (Bondi et al., 2008). The activation of MAPK is
terminated by a group of dual-specificity MAPK phosphatases, known as DUSPs or
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MKPs, tyrosine phosphatases and serine/threonine phosphatases that can act upon
tyrosine and serine/threonine residues (Zheng and Guan, 1993; Keyse, 2000). Blocking
these phosphatases leads to prolonged MAPK activation.
At least four members of the MAPK family have been identified: extracellularsignal-regulated kinases 1 and 2 (ERK1/2), ERK5, c-Jun-amino-terminal kinase (JNK),
and p38 (Fig. 4; Nishida and Gotoh, 1993; Robinson and Cobb, 1997; Cavanaugh, 2004;
Nithianandarajah et al., 2012). Among these four MAPK pathways, ERK1/2 and ERK5
MAPKs are activated by growth factors and hormones, while the remaining two, JNK
and p38 MAPKs are activated in response to cellular stress.
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Figure 4: Mitogen-activated protein kinase (MAPK) signaling
There are four major mammalian MAPK subfamilies: ERK1/2, ERK5, p38, and JNK. A
MAP Kinase Kinase Kinase (MAPKKK) phosphorylates and activates a MAP Kinase
Kinase (MAPKK), and then MAPKK phosphorylates and activates a MAP Kinase
(MAPK). GPCRs - G-protein-coupled receptors, IL-β – Interleukin-beta, UV –
Ultraviolet irradiation, CREB - cAMP response element binding protein, MEF2C Myocyte enhancer factor 2C, MEF2A - Myocyte enhancer factor 2A, Serum- and
glucocorticoid-regulated protein kinase – SGK, p90 ribosomal S6 kinase - p90RSK.
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1.6.1 ERK1 and ERK2 (Referred to as ERK1/2)
ERK1 and 2 activation is important for a multitude of functions, including cell
proliferation, differentiation, cell survival, and cell death events (Chen et al., 2001) These
two ERK isoforms, ERK1 (44 kDa) and 2 (42 kDa) are 84% homologous in amino acid
sequence and activate the same downstream substrates due to similar substrate
recognition properties and subcellular localization (Segers and Krebs, 1995). They are
shown to be activated by the same cellular stimulants leading to parallel activation of
ERK1 and ERK2. Interestingly, the activation ratio of ERK1/ERK2 in cells corresponds
to their expression ratio, indicating their parallel activation profile (Lefloch et al., 2008).
It is assumed that ERK1 and ERK2 functions are equivalent; however, recent studies
have elucidated functional differences between the kinases (Vantaggiato et al., 2006;
Marchi et al., 2008; Roskoski, 2012). For example, knockdown of erk2 in mice has
shown to be embryonic lethal (Yao et al., 2003; Hatano et al., 2003; Saba-El-Leil et al.,
2003), while erk1 is dispensable for the development of mice. Knockdown of erk1 only
caused deficits in tymocyte maturation and subtle alterations in synaptic plasticity and
behavior, with no effect on viability, fertility, or body size (Pages et al., 1999;
Mazzucchelli et al., 2002; Nekrasova et al., 2005). Furthermore, in neuronal-like NIH
3T3 cells, erk1 knockdown has been shown to facilitate growth, while erk2 knockdown
inhibited the growth (Vantaggiato et al., 2006).
ERK1 and ERK2 are activated by MEK1 and MEK2, which belong to the
MAPKK family. The activation of MEK1 and MEK2 is via MAPKKK-mediated
phosphorylation, which includes members of the Raf family, as well as Mos and
Tpl2/Cot. Raf activators include small GTPases, Ras or Rap3. MEK1 and 2-mediated
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phosphorylation of ERK1 and 2 occurs on threonine and tyrosine residues (T-E-Y).
MEK1 and MEK2 activate ERK1 and ERK2 through phosphorylation of activation loop
residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Once phosphorylated, ERK1 and 2
(Fig. 5) translocate into the nucleus where it activates nuclear transcription targets, such
as Elk1, cAMP response element binding protein (CREB), c-Myc, c-Fos and protein
kinases, such as p90 ribosomal S6 kinase (p90RSK), to induce gene expression (Yu et al.,
2001; Hu et al., 2004; Cavanaugh et al., 2006) or remain in the cytoplasm and activate
cytosolic proteins (Bondi et al., 2008). The rate of translocation of ERK1 and ERK2
depends on the phosphorylation status (Fujioka et al., 2006; Marchi et al., 2008). Marchi
and colleagues (2008) observed that ERK1 shuttles between the nucleus and cytoplasm at
a much slower rate than ERK2 and this functional difference is associated with the Nterminal domain of ERK1. Furthermore, differences in the ability of ERK1 and ERK2 to
interact with the upstream MEK activator and nucleocytoplasmic trafficking have been
noted (Vantaggiato et al., 2006; Marchi et al., 2008) that could result in lower signaling
output of ERK1 as compared to ERK2.
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Figure 5: ERK1 and ERK2 cytoplasmic and nuclear localization
ERK1/2 does not contain nuclear localization signal (NLS) and nuclear export signal
(NES) domain. However, an NES domain is found on MEK1/2 (Fukuda et al, 1996),
which is bound to ERK1/2 when MEK1/2 and ERK1/2 are not phosphorylated. This NES
domain target MEK 1/2 to the cytoplasm (Kolch, 2005), thereby, the MEK1/2 / ERK1/2
complex. Therefore, MEK1/2 retains ERK1/2 in the cytoplasm through direct interaction
(Fukuda et al, 1996). Following activation of MEK1/2, ERK1/2 is phosphorylated,
dissociates from MEK1/2, and translocate to the nucleus. Once ERK1/2 gets
dephosphorylated in nucleus by phosphatases, the ERK1/2 binds to the MEK1/2 that has
entered into nucleus through passive diffusion (Adachi et al, 2000; Yao et al, 2001). This
complex is then exported out of nucleus.
Adapted from Nishimoto, S., Nishida, E., 2006. MAPK signalling: ERK5 versus ERK1/2.
EMBO Rep. 7, 782-786.

The inactivation/de-phosphorylation of ERK1 and ERK2 is carried out by
tyrosine, serine/threonine, or both tyrosine and threonine (dual-specificity) MAPK
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phosphates, known as DUSPs or MKPs (Owens and Keyse, 2007; Roskoski, 2012). The
tyrosine-specific MKPs include protein tyrosine phosphatases-SL (PTP-SL), striatalenriched PTP (STEP), and hematopoietic specific cytoplasmic PTP (HePTP), whereas the
serine/threonine-specific MKPs include protein phosphatase 2A and 2CA (Roskoski,
2012). A single removal of two phosphates on the activated ERK2 has shown to
inactivate the kinase (Anderson et al., 1990). Among DUSPs, three closely related
cytoplasmic phosphatases DUSP6/MKP-3, DUSP7/MKP-X and DUSP9/MKP-4 have
shown preferentially to inactivate ERK1 and ERK2 (Owens and Keyse, 2007).
1.6.1.1 Neuronal roles of ERK1 and ERK2 in vitro and in vivo
In the nervous system, ERK1 and 2 have been shown to play roles in several
biological processes, including neuronal differentiation, memory formation, plasticity,
and neuronal survival (Adams et al., 2002; Hetman and Gozdz, 2004). Among several
pro-survival signaling molecules, ERK1 and ERK2 has been shown to play a
neuroprotective role in wide range of neurons or neuronal cells (Xia et al., 1995;
Cavanaugh et al., 2006; Hsuan et al., 2006; Gu et al., 2009). Many neuroprotective
agents, such as luteolin (Wruck et al., 2007), GDNF (Ugarte et al., 2003), and bFGF
(Hsuan et al., 2006) have shown to protect neurons or neuronal cells against MPTP, 6OHDA, or rotenone-induced neurotoxicity through activation of ERK1 and 2. In
dopaminergic MN9D cells, activation of ERK1and 2 haves also shown to promote basal
survival and cell survival following exposure to oxidative stress stimuli (Cavanaugh et
al., 2006; Gu et al., 2009). Numerous in vivo studies have also indicated roles for ERK1
and 2 in neuronal protection. For example, a study by Troadec and colleagues (2002)
reported that activation of the ERK1 and ERK2 signaling by cyclic AMP potentiated the
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neuroprotective effect of noradrenaline on dopamine neurons. Additionally, Pernet and
colleagues (2005) observed that ERK1 and 2 is important for the regulation of adult RGC
survival, in vivo, after traumatic injury.
The neuroprotective properties of ERK1and ERK2 have been associated with the
anti-apoptotic properties of these kinases, which include phosphorylation and subsequent
inactivation of pro-apoptotic members of the Bcl-2 family of proteins, Bim and BAD
(Hetman et al., 2004; Hsuan et al., 2006). Neuroprotection by ERK1 and 2 may also be
due to increases in expression of anti-apoptotic proteins, such as Bcl-xL and Bcl-2,
following activation of CREB by ERK1 and 2 (Hetman et al., 2004; Creson et al., 2009).
Neurotrophic and neurotrophin factors that are important for the survival of
neurons, such as GDNF, BDNF, and bFGF, have been shown to activate ERK1 and 2
signaling (Hetman et al., 1999; Cavanaugh et al., 2001; Coulpier and Ibanez, 2004;
Hsuan et al., 2006; Lindgren et al., 2012). Moreover, transcription of and release of these
growth factors from astrocytes or neurons under normal conditions, in response to stress
or stimulation occurs following activation of ERK1 and 2 signaling (Su et al., 2011; Di
Benedetto et al., 2012).
1.6.1.2 The Role of ERK1 and ERK2 in Apoptosis
Although activation of ERK1 and 2 is generally associated with neuronal
protection, these kinases have also been shown to play a role in promoting neuronal cell
death in oxidative stress models both in vitro (Jiang et al., 2000; Kulich and Chu, 2001;
Lesuisse and Martin, 2002; Gomez-Santos et al., 2002; Subramaniam et al., 2003, 2004)
and in vivo (Alessandrini et al., 1999; Namura et al., 2001; Wang et al., 2003). The
proapoptotic roles of ERK1 and ERK2 depend upon the cell type, the stimulus, and the
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duration of activation (Zhuang and Schnellmann, 2006). The intrinsic and extrinsic
pathways involved in ERK1 and ERK2-mediated apoptosis, include depolarization of the
mitochondria membrane, induction of expression of the proapoptotic protein p53, release
of cytochrome c, and activation of caspase-3 or caspase-8 (Zhuang and Schnellmann,
2006).
1.6.2 ERK5
Extracellular-signal-regulated kinase 5 (ERK5, 814 amino-acids, 125 kDa) is a
new member of the mitogen-activated protein kinase (MAPK) family and similar to
ERK1 and 2 contains the Thr–Glu–Tyr (TEY) activation motif (Fig. 6). Also similar to
ERK1 and ERK2, ERK5 is activated by growth factors and has been shown to play an
important role in numerous cellular processes including regulation of cell proliferation,
differentiation, neurogenesis, and neuronal survival (Watson et al., 2001; Hayashi and
Lee, 2004; Cavanaugh, 2004; Wang and Tournier, 2006; Pan et al., 2012). Knockdown of
the erk5 or mek5 gene has shown to be embryonic lethal due to multiple defects in
cardiovascular, angiogenesis, and placental and embryonic development (Regan et al.,
2002; Yan et al., 2003; Wang et al., 2005). ERK5, also known as big MAP kinase 1
(BMK1) and mitogen-activated protein kinase 7, is twice the size of other MAPKs (Lee
et al, 1995; Zhou et al, 1995). In 1995, two groups Lee et al. (1995) and Zhou et al.
(1995) simultaneously cloned ERK5. These were the first studies to note that ERK5
contains the TEY activation motif and shares sequence homology with ERK1 and ERK2
(Lee et al, 1995; Zhou et al, 1995). The kinase domain of ERK5 shares 66% sequence
homology to the kinase domain of ERK2 (Zhou et al., 1995). The distinguishing
structural feature of ERK5, as compared to ERK1 and ERK2, is the presence of a large
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C-terminal (410 amino acids) and a unique loop-12 sequence (Lee et al, 1995;
Nithianandarajah et al., 2012). A nuclear localization signal (NLS) domain exists within
the C-terminal domain, (Fig. 6). This NLS domain is important for ERK5 nuclear
targeting (Buschbeck et al., 2005).
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Figure 6: Structure of ERK5 and functional domains
ERK5 consists of 816 amino acids (a.a.) residues. In the N-terminus, there is kinase
domain that contains the MEK5 binding site. In the C-terminal of ERK5, there are two
proline rich domains (PR1 and PR2), nuclear localization signal (NLS), and nuclear
export signal. NES is also present in the N-terminus.
Image adapted from Nithianandarajah-Jones, G.N., Wilm, B., Goldring, C.E., Müller, J.,
Cross, M.J., 2012. ERK5: Structure, regulation and function. Cell.Signal.
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Figure 7: ERK5 cytoplasmic and nuclear localization
Nucleocytoplasmic shuttling of ERK5 is controlled by its own N-terminal half and Cterminal half and these processes are phosphorylation-dependent control mechanism
(Kondoh et al., 2006). ERK5 has nuclear localization signal (NLS) in its carboxyterminal region. In the resting, non-phosphorylated state, both the N-terminal and Cterminal produce a nuclear export signal (NES). The NES is recognized by cytoplasmic
anchor proteins helping to retain ERK5 in the cytoplasm. Once phosphorylated by
MEK5, the dissociation between the N- and C-terminal halves occur, resulting in a loss of
NES activity, causing the nuclear import of ERK5.
Image adapted from Nithianandarajah-Jones, G.N., Wilm, B., Goldring, C.E., Müller, J.,
Cross, M.J., 2012. ERK5: Structure, regulation and function. Cell.Signal.
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ERK5 is activated directly by MEK5, a specific MAPKK for ERK5, in a growth
factor-dependent, Ras-independent mechanism (Kato et al., 1997, 1998; Dong et al.,
2001). The activation of MEK5 is through MEKK2 and MEKK3, members of the
MAPKKKs family (Chao et al., 1999; Sun et al., 2001). MEK5 activates ERK5 through
dual phosphorylation of Thr218 and Tyr220 in the activation loop of the kinase domain
(Mody et al., 2003) (Fig. 7). Further, activation of ERK5 leads to ERK5
autophosphorylation in its unique C-terminal domain (Morimoto et al., 2007). This
phosphorylated ERK5 regulates gene expression through its C-terminal transcriptional
activation domain (Morimoto et al., 2007). Once phosphorylated, ERK5 translocates into
the nucleus where it activates nuclear myocyte enhancer factor 2 family members, such
as MEF2C, and other transcription targets including c-Fos, Fos-related antigen-1(Fra-1),
Serum- and Glucocorticoid-regulated protein Kinase (SGK) and Sap1a (Kato et al., 1997,
1998; Kamakura et al., 1999; Hayashi et al., 2001; Terasawa et al., 2003).
Nucleocytoplasmic shuttling of ERK5 is controlled by its own N-terminal half and Cterminal half and these processes are phosphorylation-dependent

mechanisms

(Buschbeck et al., 2005; Kondoh et al., 2006). Binding of the N- and C- terminal halves
of ERK5 is important for nuclear export of ERK5, while phosphorylation of ERK5 by
MEK5 results in the dissociation of the binding between the N- and C-terminal halves
and thus inhibits nuclear export of ERK5. Unlike ERK1 and ERK2, the DUSPs or MKPs
that dephosphorylate Thr218 and Tyr220 of ERK5 are not clearly identified.
1.6.2.1 Neuronal roles of ERK5 in vitro and in vivo
In the CNS and PNS, ERK5 has been indicated for several biological processes,
including neuronal differentiation, migration, neurogenesis, neutrite outgrowth,
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development, memory formation, and neuronal survival (Watson et al., 2001; Liu et al.,
2003, 2006; Cavanaugh, 2004; Cundiff et al., 2009; Obara et al., 2009; Pan et al., 2012;
Zou et al., 2012; Li et al., 2013). Specifically, in response to diverse neurotrophic prosurvival stimuli, ERK5 signaling has shown to be crucial for neuronal cell survival and
development (Cavanaugh et al., 2001; Watson et al., 2001; Liu et al., 2003, 2006; Shalizi
et al., 2003; Finegan et al., 2009). Activation of ERK5 signaling has been shown to be
important for the regulating release of neurotrophic and neurotrophin factors, such as
GDNF and BDNF, from astrocytes under normal conditions (Obara et al., 2011; Su et al.,
2011).
A study by Liu et al. (2006) suggests that ERK5 is crucial for basal cortical
neuronal survival during development. In this study, a decrease in ERK5 expression in
embryonic cortical neurons (E17) resulted in a loss of BDNF-mediated neuroprotection
from serum withdrawal. Furthermore, during the neurogenic period of cortical
development, these investigators observed an increase in the expression of activated
ERK5 (Liu et al., 2006). Furthermore, when E13 cortical progenitor cells were exposed
to ciliary neurotrophic factor (CNTF), ERK5 expression was crucial for their
neurogenesis (Liu et al., 2006). In a separate study, neurogenin 1-mediated cortical
neurogenesis was also inhibited when ERK5 signaling was blocked (Cundiff et al., 2009).
Similar to these studies in cortical neurons, a report by Shalizi and colleagues (2003)
shows that inhibition of ERK5 signaling in immature cerebellar neurons resulted in a loss
of BDNF-mediated neuroprotection from trophic factor withdrawal.
Numerous in vivo studies also have indicated a crucial role for ERK5 in
neurogenesis, neuronal development, and survival (Zou et al., 2012; Li et al., 2013).
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Higher expression of ERK5 has been observed during embryonic and postnatal
development of the brain, specifically the cortex, as compared to expression in the mature
brain (Liu et al., 2003, 2006). Conditional deletion of ERK5, specifically in the adult
neurogenic regions, has been shown to delay the normal progression of neuronal
differentiation and attenuation of adult neurogenesis in vivo (Pan et al., 2012; Wang et al.,
2013)
Neuroprotective properties of ERK5 are associated with modulation of antiapoptotic and pro-apoptotic signaling proteins. A study by Finegan et al. (2009) reported
that ERK5 regulates apoptosis through inhibition of pro-apoptotic protein expression and
transcription, including Bad, and Bim.
1.6.2.2 The Role of ERK5 in Apoptosis
So far, only one study has reported a role for ERK5 in the induction of apoptosis
(Sturla et al., 2005). In two medulloblastoma cell lines and primary cultures of mouse
medulloblastomas, overexpression of ERK5 increased apoptosis (Sturla et al., 2005).
Also, when expression of MEK5 was inhibited using small interfering RNA,
neurotrophin-3 induced apoptotis was blocked (Sturla et al., 2005). Moreover,
overexpression of a dominant-negative mutant of MEF2, a specific downstream target of
ERK5, resulted in inhibition of MEK5/ERK5-induced cell death (Sturla et al., 2005).
1.6.3

MAPK signaling: ERK5 versus ERK1 and ERK2
Structurally, ERK5 is twice the size of other MAPKs (Lee et al, 1995; Zhou et al,

1995). The carboxyl-terminal half in ERK5 is unique as compared to ERK1 and ERK2,
while the amino-terminal half that contains the kinase domain is similar to that of ERK1
and ERK2. The upstream and downstream targets of ERK5, and ERK1 and 2 are
42

different. ERK5 is activated specifically by upstream components, such as Ras, MEKK2,
MEKK3, and MEK5, while ERK1 and ERK2 are activated specifically by upstream
components, such as Raf family members and MEK1 and 2. Downstream target of ERK5
includes myocyte enhancer factor 2 family members, such as MEF2C and MEF2A (Kato
et al., 1997, 1998; Cavanaugh et al., 2001), while ERK1 and 2 activates downstream
target such as Elk1 (Hu et al., 2004). However there are common downstream targets of
ERK1 and ERK2, and 5, such as the c-Myc, c-Fos, CREB and Sap1a transcription factors
(Gille et al., 1992; Cavanaugh et al., 2006).
1.7

Fisher 344 x Brown-Norway F1 rat: Animal model to study nigrostriatal
system deficiency with aging
The Fisher 344 x Brown-Norway F1 (F344xBN F1, a hybrid strain) is a widely

used rat model to study age-related pathologies due to decreased variability in several
physiological and behavioral measures (Phelan and Austad, 1994). This strain displays
advantages over other strains commonly used for aging studies, such as Fisher 344
(F344), Brown-Norway (BN), and Sprague Dawley (SPD). Some of the advantages of the
F344xBN F1 strain include: 1) age-related pathologies occur relatively late in life
(Lushaj et al., 2008), thereby, decreasing the rate of mortality, 2) 50% mortality is
attained at 146 weeks of age as compared to 103 and 130 week of age for F344 and BN,
respectively (Lipman et al., 1996), 3) low incidence of renal pathology is observed as
compared to aged Fisher 344 (Lipman et al., 1996), and 4) no specific tumor
susceptibilities, known to occur in alternative rat models of aging, have been observed.
With respect to the nigrostriatal system, the age-related changes in both the
striatum and midbrain of F344xBN F1 rats are comparable to that observed in aging
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primates and humans (Allard and Marcusson, 1989; Spangler et al., 1994; Yurek et al.,
1998; Troiano et al., 2010; Horner et al., 2011). These similarities allow for the study of
age-related motor dysfunction and changes that occur in the dopaminergic system with
normal aging. As compared to BN and F344, F344xBN F1 rats exhibit a greater reduction
in locomotor activity with age (Spangler et al., 1994). Decreases in locomotor or motor
performance, and lower levels of spontaneous and D-amphetamine-induced locomotor
activity is observed in old F344XBN F1 rats as compared to young (Yurek et al., 1998;
Salvatore et al., 2009; Horner et al., 2011). Further, in middle-aged and old F344xBN F1
rats, fewer TH-IR neurons were observed in the substantia nigra and lower extracellular
levels of DA, DOPAC, and HVA were detected in the striatum as compared to young
animals (Yurek et al., 1998; Fox et al., 2001). Decreased tissue levels of DA were also
observed in the ventral striatum and midbrain in the old-aged F344xBN F1 as compared
to young rats (Yurek et al., 1998; Salvatore et al., 2009; Salvatore and Pruett, 2012).
These age-related declines in DA neurochemistry are well correlated with diminished
motor function in this aged animal model (Yurek et al., 1998). Levels of tyrosinehydroxylase proteins have also been found to decline with age in the striatum and
substantia nigra of old F344xBN F1 rats (Salvatore et al., 2009; Salvatore and Pruett,
2012; Dickerson et al., 2009). A decline in DAT protein expression was also observed in
this strain (chapter 2), similar to the decline in DAT levels observed with normal aging in
primates and humans (Allard and Marcusson, 1989; Troiano et al., 2010).
Neurotrophic factors such as GDNF and neuregulins have been shown to be
important for the survival of dopaminergic neurons against neurotoxin-induced oxidative
stress (Fox et al., 2001; Carlsson et al., 2011). With aging, a significant reduction in the
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level of GDNF protein in the striatum and ventral midbrain has been observed in this
strain (Yurek and Fletcher-Turner, 2001). Expression levels of the neurotrophic factor
receptors, GDNF receptor GDNF family receptor α-1 (GFRα-1) and the neuregulin
receptor ErbB4, also significantly decrease with normal aging in the substantia nigra of
F344xBN F1 rats (Dickerson et al., 2009; Pruett and Salvatore, 2010). The deficiency in
the GDNF- GFRα-1 and NRG- ErbB4 mediated signaling with normal aging could be
contributing to a decline in DA neurons and DA levels, thereby reducing locomotor
activity.
Overall, the comparable deficiency in the dopaminergic system of normal aging
F344xBN F1 rats to that observed in primates makes them an appropriate model to study
neurochemical, molecular, and cellular alterations in the aging nigrostriatal system as
seen in human aging and early Parkinson's disease.
1.8

6-Hydroxyamine
6-hydroxyamine (6-OHDA) is a widely used neurotoxin for in vitro and in vivo

studies to induce oxidative stress in the catecholaminergic neurons, especially dopamine
neurons. It is a hydroxylated analogue of the dopamine neurotransmitter. Due to its some
structural similarities with dopamine, it exhibits a high affinity for dopamine transporters
(DAT) that are present on the plasma membrane of dopamine neurons. It is widely used
to generate experimental models of dopamine lesions and motor impairments as observed
in PD. It has been reported that 6-OHDA have been observed to be present in both rat
(Senoh et al., 1959a, 1959b) and human brain (Curtius et al., 1974), including in urine of
L-dopa treated PD patients (Andrew et al., 1993).

45

Several mechanisms have been involved in 6-OHDA induced cell death. Once it
enters the cell, it gets easily oxidized to free radicals, such as hydrogen peroxide and
hydroxyl radicals, thereby, inducing oxidative stress. The 6-OHDA induced-oxidative
stress results in cascade of events that result in apoptosis. Such events includes: 1)
Alterations in Bcl-2 family proteins (anti-apoptotic – Bcl-2, Bcl-2 and apoptotic – Bim)
expression that are present on mitochondrial memebrane, thereby, controling
mitochondrial outer membrane potential. 2) Disturbance of mitochondrial outer
membrane potential, results in release of cytochrome c, which further result in caspase3/7 activation through series of cellular events. Caspases 3 and 7 are family of cystein
proteases, which are key mediators of mitochondrial events of apoptosis. The activation
of caspase-3/7 has been shown to induce apoptotic cell death through proteolysis of
numerous cellular proteins. 3) Direct inhibition of mitochondrial respiratory chain,
thereby, further increasing level of oxidative stress within cell. 4) 6-OHDA induced
oxidative stress also results in increase in lipid peroxidation of plasma membrane,
thereby, cytoskeleton disorganization. 5) Auto-oxidation of 6-OHDA outside the cell
results in oxidative damage to plasma membrane, thereby, cell death.
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Figure 8: Molecular pathways involved in the neurotoxicity of 6-OHDA
6-OHDA – 6-hyroxydopamine; DAT – Dopamine transporter; H2O2 – Hydrogen
peroxide; MAO - Monoamine oxidase. Image from Blum et al. 2001.
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In summary, the objectives of these study were to determine 1) the age-related
changes in the total (non-phosphorylated) and phosphorylated protein expression of
ERK1, ERK2, and ERK5 in the dopaminergic regions, SN, STR, and VTA, 2) the role of
ERK1, ERK2, and ERK5 in the basal survival of dopaminergic neurons from SN, and
VTA, and 3) the neuroprotective properties of GDNF and DNSP-11 in human
dopaminergic SH-SY5Y neuroblastoma cell-line.
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Chapter 2: Role of ERK1/2 and ERK5 in dopamine neuronal survival
2.1

Rationale
Extracellular signal-regulated kinases (ERK) 1, 2, and 5 are members of the

mitogen-activated protein kinase (MAPK) family that regulate many physiological
processes during neurodevelopment, including apoptotic cell death and the maintenance
of neuronal viability following oxidative insults (Xia et al., 1995; Liu et al., 2003; 2006;
Cavanaugh, 2004; Watson et al., 2001; Satoh et al., 2011). Age-associated changes in
ERK1 and ERK2 expression and activation have been observed, although the nature of
these changes is controversial. For example, Song and colleagues (2007) reported an
increase in phosphorylated ERK1 and 2 (p-ERK1 and p-ERK2, respectively) levels in the
hippocampus, frontal cortex, and striatum in 24-month old animals. However, Mo and
colleagues (2005) demonstrated a decrease in p-ERK1 and p-ERK2 levels in these same
brain regions in 22-month old rats. Although ERK5 expression has not been studied in
the aging brain, Liu and colleagues (2003; 2006) observed high levels of ERK5 in early
embryonic stages that decreased in the whole brain and cortex of postnatal and adult
Sprague-Dawley rats.
To date, no studies have been performed to examine the relative expression and
activation of ERK1, ERK2, and ERK5 in dopaminergic regions of the brain with aging or
their roles in the survival of dopamine (DA) neurons. Although ERK5 has been shown to
be crucial for the basal survival of MN9D dopaminergic cells (Cavanaugh et al., 2006),
its role in the survival of primary DA neurons has not been explored. In this study, we
examined the expression and activation of ERK1, ERK2, and ERK5 in the SN, STR, and
VTA during aging. Further, we examined the relative roles of these ERK isoforms in DA
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neuronal survival. Due to the involvement of dopaminergic neuronal systems in
Parkinson’s disease and other mental disorders, elucidation of cellular signaling
alterations that may be responsible for the decrease in dopaminergic function with age
may advance our understanding of neurological disorders and lead to the identification of
novel drug targets for these conditions.
2.2

Hypothesis

With age, ERK5 expression and activation decreases, while ERK1/2 increases in
dopaminergic brain regions.
2.3

Materials and Methods

2.3.1

Animals
To determine ERK expression in the SN, STR, and VTA with age, young (3 mo.),

middle-aged (13 mo.), and old (23 mo.) male Fisher 344 x Brown-Norway F1 hybrid
(F344xBN F1) rats were obtained from the National Institute on Aging colonies (Harlan
Sprague-Dawley, Indianapolis, IN). For primary neuronal cultures, timed pregnant
Sprague-Dawley rats (Hilltop Laboratory Inc., Scottdale, PA) were used. Animals were
single-housed in a 12:12 light: dark cycle and provided with water and rat chow ad
libitum. All procedures were conducted in accordance with the guidelines for the NIH
Care and Use of Laboratory Animals and approved by the Duquesne University or the
University of Pittsburgh Institutional Animal Care and Use Committees.
2.3.2

Materials and tissue preparation
For western blot analysis, tissue samples were sonicated in ice-cold 1:20 (w/v)

homogenation lysis buffer (20 mM Tris, pH 6.8, 137 mM NaCl, 25 mM βglycerophosphate, pH 7.14, 2 mM NaPPi, 2 mM EDTA, 1 mM Na3VO4, 1% Triton X50

100, 10% glycerol, 5 μg/ml leupeptin, 5 μg/ml aprotinin, 2 mM benzamidine, 0.5 mM
DTT and 1 mM PMSF) using a 2% pulse. Total homogenate was centrifuged at 11,000
rpm for 30 min at 4 ºC and the supernatant was collected and stored at -80 ºC until
analysis.
2.3.3

Western blot analysis
Total protein content was assessed by Bradford Bio-Rad protein assay (Cat. No.

500-0006, Bio-Rad, Hercules, CA) and 60 μg of protein was loaded on an 8% SDSPAGE gel and transferred to a nitrocellulose membrane (Cat. No. 926-31092, Licor
Biosciences, Lincoln, NE). After transfer, membranes were washed for 5 min with 1X
PBS and blocked for 1 h in a casein blocking buffer (Cat. No. 927-40200, Licor
Biosciences) at room temperature. Membranes were then incubated overnight at 4 ºC in
primary antibody in casein blocking buffer with 0.1% Tween-20. Antibodies included
rabbit anti-phospho-ERK1/2 (Dilution – 1:1000, Cat. No. 9101, Cell Signaling, Beverly,
MA), mouse anti-total ERK1/2 (Dilution – 1:2000, Cat. No. 9107, Cell Signaling), rabbit
anti-phospho-ERK5 (Dilution – 1:500, Cat. No. 3371, Cell Signaling) and rabbit antitotal ERK5 (Dilution – 1:1,000, Cat. No. E1523, Sigma-Aldrich, St. Louis, MO). Mouse
anti-α-Tubulin (Dilution – 1:10,000, Cat. No. T5168, Sigma–Aldrich) was used as a
loading control. After incubation with primary antibody, blots were washed in 1X PBS
solution with 0.1% Tween-20 (1X PBS-T) and incubated with goat anti-rabbit (Dilution –
1:20,000, Cat. No. 926-68021, Licor Biosciences) and goat anti-mouse (Dilution – 1:
20,000, Cat. No. 926-32210, Licor Biosciences) secondary antibodies for 1 h at room
temperature. After washing the membranes with 1X PBS-T, the protein bands were
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visualized on an Odyssey Infrared Imager and quantified with Odyssey software (Licor
Biosciences).
2.3.4 Primary dissociated dopaminergic SN and VTA neuronal culture and
treatment
Cultures were prepared as described in Ding et al, 2004 with minor modifications.
Postnatal day 0 rat brains were isolated under sterile condition into cold Gey’s Balanced
Salt Solution (1.55 mM CaCl2, 5 mM KCl, 0.22 mM KH2PO4, 1.05 mM MgCl2, 137 mM
NaCl, 2.7 mM NaHCO3, 0.84 mM NaH2PO4, and 5.5 mM glucose pH 7.25). Coronal
sections of the SN and VTA were isolated under a dissecting microscope. The tissue was
then incubated in a solution containing 20 units/ml of papain and dissolved in a
disassociation media (DM) containing 90 mM Na 2SO4, 30 mM K2SO4, 5.8 mM MgCl2,
0.25 mM CaCl2, 10 mM 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES),
20 mM glucose, 0.5% phenol red, 1 mM kynurenic acid and 10 mM MgCl2 for 1 h in a
roller drum incubator (Schuett-biotec Gmbh, Göttingen, Germany) at 35 C. After
incubation in the papain, the tissue was washed several times in DM, followed by washes
in trituration media (TM; 1 mg/ml Bovine Serum Albumin (BSA), 10 mM Hepes,
1mg/ml trypsin inhibitor, 1 mM kynurenic acid, 10 mM MgCl2, 5% fetal bovine serum),
then finally two washes with feeding media (FM; 2% rat serum, 2% fetal bovine serum,
B27 Supplement Supplement (Life Technologies, Grand Island, NY), 0.225% glucose, 1
mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 10 mM Hepes, and
0.9 mM sodium pyruvate in BME). After washing, the tissue was mechanically
dissociated with a fire-polished pipet in TM. The slurry of cells was put through a
concentration gradient 10mg/ml BSA, 10mg/ml trypsin inhibitor, 1 mM kynurenic acid,
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10 mM MgCl2, 5% fetal bovine serum in BME to concentrate neurons and remove debris.
The pellet was resuspended in FM. Cells were plated on 16 well Nunc chambered slides
(Thermofischer Scientific, Pittsburgh, PA), coated with 200 µg/ml poly-d-lysine and 5
µg/ml laminin (Life Technologies) at a concentration of 30,000 live cells/well determined
by trypan blue cell exclusion with a hemocytometer. Cultures were maintained at 37 C
in 5% CO2. As soon as the cultured primary cells were attached to the plate (at least one
hour following plating), the treatments with DMSO and MEK inhibitors, BIX02189
(Selleck Chemicals, Houston, TX) or U0126 (Sigma-Aldrich) (all 10 µM), were
performed for different time points (0, 1, 6, 12, and 24 h).
2.3.5 Immunocytochemical staining
At 2, 4, 6, and 8 days in vitro (DIV) slides were fixed in 4% paraformaldehyde
and 4% sucrose in PBS for 30 min. The slides were washed 3 times in wash buffer (0.1%
Tween 20, sodium azide in PBS). Following washes, the slides were incubated in
blocking solution of 5% BSA (Sigma-Aldrich), 0.1% glycine, 5% goat serum (Jackson
Immuno, West Grove, PA), and 0.3% Triton X-100 (Bio-Rad) in PBS with sodium azide
for 1 h. After blocking, cultures were incubated in rabbit anti-TH antibody (PelFreez,
Rogers, AR) overnight at a concentration of 1:5000 in blocking buffer. Following three
washes, the cultures were incubated with Alexa Fluoro 546 goat anti-mouse (1:1000,
Molecular Probes, Life Technologies) in blocking buffer 2 h and Hoechst 33342 (10
μg/ml) for 15 min. The slides were washed and cover slipped with Fluoromount
(Southern Biotech Birmingham, AL).
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2.3.6 Data Collection and Image Analysis for TH+ and Hoechst counting
Images were captured with MetaMorph Imaging Software (7.1, Universal
Imaging, Downingtown, PA) using a Retiga 1300R digital CCD camera (QImaging,
Burnaby, British Columbia, Canada). TH+ cells and total cell number were obtained
using the cell count macro within the MetaMorph software after verifying the accuracy
with manual counting of the cells.
2.3.7 SH-SY5Y cells culture and treatment
Human dopaminergic neuroblastoma SH-SY5Y cells were cultured in DMEM
(Cat. No. 11965-084, Life Technologies) supplemented with 10% (v/v) fetal bovine
serum (Cat. No. S11550, Atlanta Biologicals, Atlanta, GA), 0.05 units/ml penicillin and
0.05 mg/ml streptomycin (Cat. No. P0781, Sigma-Aldrich) and maintained at 37 ºC in a
humidified 5% CO2 atmosphere. For treatment with inhibitors, SH-SY5Y cells were
seeded in 96-well plates (Cat. No. 3603, Black plate with clear bottom, Corning
Incorporated, Corning, NY) at a density of 15,000 cells/well. Cell viability was assessed
after 24 and 48 h of U0126 (10 µM) or BIX 02189 (10 µM) exposure.
2.3.8

CellTiter-Glo® Luminescent Cell Viability Assay
Cell viability was detected in 96-well (Cat. No. 3603, Black plate with clear

bottom, Corning Incorporated) format using CellTiter-Glo® Luminescent Cell Viability
Assay (Cat. No. G7570, Promega Inc., Madison, WI). This assay is based on a
luciferase/luciferin reaction. In presence of Mg2+ and ATP, luciferase/luciferin produces
oxyluciferin and releases energy in form of luminescence. As this reaction requires ATP,
the luminescence produced is proportional to the amount of ATP present. The amount of
ATP is directly proportional to the number of metabolically active viable cells.
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Briefly, to determine SH-SY5Y viability, the 96-well plate was taken from the
incubator and brought to room temperature, and 25 µl of Cell Titer-Glo mixture were
added to each well containing 50 µl media. The cells were then lysed by shaking the plate
at high speed for 10 min on shaker. After 10 min, Luminescence was measured on a
microplate reader (Victor3 1420 multilabel counter, PerkinElmer, MA).
2.3.9

Statistical Analysis
GraphPad Prism 5 Software (San Diego, CA) was used for statistical analysis.

Data are expressed as mean ± SEM. For the aging study, statistical comparison was
performed using a one-way analysis of variance (ANOVA) followed by the appropriate
post hoc test as noted for each analysis. A two-tailed Student's t-test for unpaired data
was also used for statistical comparisons. For viability studies, statistical significance was
determined by two-way ANOVA followed by the Bonferroni post hoc test. Statistical
significance was defined at p < 0.05.
2.4

Results

2.4.1 Age-related changes in ERK1, ERK2, and ERK5.
No age-related changes were observed in total ERK5 expression in the SN, STR,
or VTA (Figs. 9-11), but found a decrease in p-ERK5 in old and middle-aged animals as
compared to young animals in the SN and STR (Figs. 9 and 10, respectively). The decline
in p-ERK5 with aging was observed when the ratio of p-ERK5 was taken with either αtubulin or total ERK5. No p-ERK5 expression was detected in the VTA (Fig. 11), which
could be due to either low ERK5 expression or low phosphorylation in this region.
In contrast to ERK5, age-related increases in total ERK1 expression were
observed in the SN, STR, and VTA (Figs. 9-11). In the SN and VTA, no significant
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changes were observed in ERK2 expression but in the VTA a trend increase in ERK2
expression was observed starting at middle age (Figs. 9-11). This trend is significant
when the young and middle age groups were compared using student’s t-test (p = 0.023,
Fig. 11). We did not observe any significant changes in p-ERK1 and p-ERK2 with age in
SN (Fig. 9) or VTA (Fig. 11). However, an increase in p-ERK2 was observed in the STR
starting at middle age (Fig. 10) when the ratio of p-ERK2 was taken with either α-tubulin
or total ERK2. In the VTA, trending decreases in the amount of p-ERK1 and p-ERK2
were observed with age when the ratio of p-ERK1 and p-ERK2 were taken with total
ERK1 and total ERK2, respectively (Fig. 11). However, this trend was not significant.
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Figure 9: Total and phosphorylated ERK1, ERK2, and ERK5 expression in the
substantia nigra (SN) from young, middle-aged, and old male F344xBN F1 hybrid
rats
A) Immunoblot analysis of total and phosphorylated ERK1, ERK2, and ERK5 expression
in the SN.
B) Quantification of the immunoblots using Licor Odyssey software. The values are
calculated using the integrated intensity. Protein expression was standardized to αTubulin and basal total protein. n=10 for each age. Data are expressed as mean ± SEM. *
p < 0.05 indicates a difference compared to the young age group. # p < 0.05 indicates a
difference compared to the middle age group. p values were determined by analysis of
variance followed by post hoc Student-Newman-Keuls.
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Figure 10: Total and phosphorylated ERK1, ERK2, and ERK5 expression in the
striatum (STR) from young, middle-aged, and old male F344xBN F1 hybrid rats
A) Immunoblot analysis of total and phosphorylated ERK1, ERK2, and ERK5
expression in the STR.
B) Quantification of the immunoblots using Licor Odyssey software. The values are
calculated using the integrated intensity. Protein expression was standardized to αTubulin and basal total protein. n=10 for each age. Data are expressed as mean ± SEM.
** p < 0.01 and * p < 0.05 compared to the young age group by analysis of variance
followed by post hoc Student-Newman-Keuls.
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Figure 11: Total and phosphorylated ERK1, ERK2, and ERK5 expression in the
ventral tegmental area (VTA) from young, middle-aged, and old male F344xBN F1
hybrid rats
A) Immunoblot analysis of total and phosphorylated ERK1, ERK2, and ERK5 expression
in the VTA.
B) Quantification of the immunoblots using Licor Odyssey software. The values are
calculated using the integrated intensity. Protein expression was standardized to αTubulin and basal total protein. n=5 for each age. Data are expressed as mean ± SEM. * p
< 0.05 indicates a difference compared to the young age group by analysis of variance
followed by post hoc Student-Newman-Keuls.
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2.4.2

U0126 and BIX02189 inhibit ERK1/2 or ERK5 activation, respectively.
In order to determine the distinct roles of the ERK isoforms in the basal survival

of DA neurons, the impact of MEK inhibitors that specifically block either ERK1 and
ERK2 or ERK5 phosphorylation was examined by western analysis in primary cultures
from the SN and VTA. It has been reported that the MEK1/2 inhibitor, U0126, also
blocks MEK5 phosphorylation, thereby inhibiting ERK1/2, and 5 activation (Kamakura
et al., 1999; Cavanaugh et al., 2006). However, others have reported that U0126 does not
inhibit ERK5 signaling (Mody et al., 2001). This suggests that the specificity of U0126
may depend on the type of cells, stimulation, and concentration used. Hence, it is
important to test whether or not U0126 blocks ERK1, ERK2, and/or ERK5
phosphorylation in our system. Results indicate that U0126 significantly blocked ERK1
and ERK2, but not ERK5, phosphorylation in primary SN and VTA cultures at any time
point or dose tested in this study (Figs. 12A and 12B).
Recently, BIX02189 was developed as a selective pharmacological inhibitor of
the MEK5/ERK5 pathway (Tatake et al., 2008; Obara et al., 2011). Results confirm that
BIX02189 (10 µM) blocked ERK5, but not ERK1 or ERK2, phosphorylation at 12 and
24 h in primary SN and VTA cultures (Figs. 12C and 12D).
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Figure 12: Inhibition of ERK1/2 and ERK5 phosphorylation by U0126 and
BIX02189, respectively
Immunoblot analysis indicating selective inhibition by U0126 (10 µM) of ERK1/2
phosphorylation in the primary dissociated neuronal culture prepared from (A) substantia
nigra and (B) ventral tegmental area. Immunoblot analysis indicating selective inhibition
by BIX02189 (10 µM) of ERK5 phosphorylation in the primary dissociated neuronal
culture prepared from (C) substantia nigra and (D) ventral tegmental area. Data are
expressed as mean ± SEM. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicates indicate a
difference compared to the no treatment by analysis of variance followed by post hoc
Student-Newman-Keuls.
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2.4.3

ERK5 is necessary for the basal survival of primary SN and VTA cultures.
To examine the role of the ERK pathways in the basal survival of DA neurons,

the SN and VTA cultures were treated with U0126 (10 µM) or BIX02189 (10 µM) on
DIV 0 until DIV 2, 4, 6, and 8. The DA neuronal and total cell viability was then
determined at DIV 2-8 by counting TH+ neurons and Hoechst-stained nuclei. As is usual
with these primary DA cultures, a decline in the number of TH + neurons and an increase
in the number of Hoechst-stained nuclei in both the SN and VTA were observed with
increasing DIV in the vehicle group. The TH+ neurons are only 5-10% of the total cells in
culture. Therefore even as the number of DA neurons decreases, the percent of total cells
may not decrease. In addition, the glia in the culture continues to divide with time. By
DIV 2, treatment of SN and VTA primary cultures with BIX02189 decreased the number
of total cells (which includes DA neurons, GABA neurons, and glia) in both the SN
(45%; Fig. 13F) and VTA cultures (47%; Fig. 14F). This effect was even more
pronounced when DA neurons were counted separately: DA neurons were reduced by
67% in SN and 69% in VTA cultures (Figs. 13E and 14E, respectively). Similarly, at
DIV 4, 6, and 8, significant losses of DA neurons and total cells were observed in the SN
and VTA cultures treated with BIX02189 as compared to the vehicle treated cells. In
contrast, U0126 treatment did not cause a significant decrease in DA neurons or total
cells in cultures of the SN (Figs. 13E and 13F) or VTA (Figs. 14E and 14F) by DIV 2. A
significant loss of DA neurons was observed at DIV 4, 6, and 8 with U0126 in the VTA
(Fig. 14E), but not SN (Fig. 13E). Similarly, a significant loss of total cells was observed
at DIV 4, 6, and 8 with U0126 in the VTA (Fig. 14F). In contrast, a significant decrease
in the total number of cells was only observed at DIV 8 in the SN following U0126
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treatment (Fig. 13F). At every time point examined the percentage loss of both DA
neurons and total cells in the SN and VTA cultures was greater following BIX02189
treatment as compared to U0126 treatment. When the ratio of the number of DA neurons
to that of total cells was determined for SN and VTA cultures, there was a significant loss
of DA neurons following BIX02189, but not U0126, treatment as compared to the
vehicle controls for all the DIV (Figs.15A and 15B).
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Figure 13: Effect of pharmacological inhibition of ERK1/2 and ERK5 phosphorylation on the basal survival of DA neurons in
primary dissociated substantia nigra cultures
At DIV 0 cultures were treated with U0126 (10 µM) and BIX02189 (10 µM) and cultures were fixed and immunostained for TH (red
fluorescence) to label DA neurons and bisbenzimide H33258 (Hoechst – blue fluorescence) to label all cell nuclei on A) DIV 2, B)
DIV 4, C) DIV 6 and D) DIV 8. Data were quantified for E) number of TH+ cells and F) number of total cells (Hoechst). Data are
expressed as mean ± SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 indicates a difference as compared to respective vehicle
treatment by two-way ANOVA followed by the Bonferroni post hoc test.
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Figure 14: Effect of pharmacological inhibition of ERK1/2 and ERK5 phosphorylation on the basal survival of DA neurons in
primary dissociated ventral tegmental area cultures
At DIV 0 cultures were treated with U0126 (10 µM) and BIX02189 (10 µM) and cultures were fixed and immunostained for TH (red
fluorescence) to label DA neurons and bisbenzimide H33258 (Hoechst – blue fluorescence) to label all cell nuclei on A) DIV 2, B)
DIV 4, C) DIV 6 and D) DIV 8. Data were quantified for E) number of TH+ cells and F) number of total cells (Hoechst). Data are
expressed as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 indicates a difference as compared to
respective vehicle treatment by two-way ANOVA followed by the Bonferroni post hoc test.
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Figure 15: Ratio of TH+ cells to total cell counts
Loss of TH+ cells with respect to total cell loss in primary dissociated neuronal cultures prepared from A) substantia nigra and B)
ventral tegmental area for all the DIV. Data are expressed as mean ± SEM. Data are expressed as mean ± SEM. * p < 0.05 indicate a
difference as compared to respective vehicle treatment by two-way ANOVA followed by the Bonferroni post hoc test.

71

2.4.4 ERK5 is necessary for basal survival of SH-SY5Y cells.
Primary dissociated SN and VTA cultures contain other neuronal cell types
(e.g., GABA neurons) and glia that have been shown to protect DA neurons against
oxidative stress (Hou et al., 1997). Thus, it is possible that the MEK inhibitors were
influencing DA neurons indirectly via the inhibition of ERK signaling in other cells. In
an attempt to examine this possibility, the effect of MEK inhibitors was tested on the
human neuroblastoma SH-SY5Y cell line which has been shown to possess many
characteristics of dopaminergic neurons, including the presence of TH and dopamine βhydroxylase and the capacity to synthesize DA (Biedler et al., 1973; Oyarce and Fleming,
1991; Cheung et al., 2009; Xie et al., 2010). SH-SY5Y cells were treated with U0126 (10
µM) or BIX02189 (10 µM) for 24 and 48 h. Our results show a loss of SH-SY5Y cell
viability with BIX02189, but not U0126, treatment at 24 and 48 h (Fig. 16).
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Figure 16: Effect of pharmacological inhibition of ERK1/2 and ERK5
phosphorylation on the basal survival of human dopaminergic neuroblastoma SHSY5Y cells
SH-SY5Y cells were treated with U0126 (10 µM) and BIX02189 (10 µM) for 24 and 48
h. After 24 and 48 h, cell viability was determined by measurement of ATP levels using a
Cell Titer-Glo Luminescent Cell Viability Assay. Data are expressed as mean ± SEM. **
p < 0.01 and *** p < 0.001 indicates a difference as compared to respective vehicle
treatment by two-way ANOVA followed by the Bonferroni post hoc test.
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2.5

Discussion
This study examined the levels of total and phosphorylated ERK 1, ERK2, and

ERK5 in several dopaminergic brain regions as a function of age. Furthermore, this study
sought to determine the importance of ERK phosphorylation in the survival of DA
neurons emanating from the SN and VTA. In contrast to previous studies in which no
ERK5 mRNA or protein expression was detected in the SN, STR, and VTA of the adult
mouse brain (Di Benedetto et al., 2007; Pan et al., 2012), detection of both total and
phosphorylated ERK5 protein in each adult brain region examined with the exception of
p-ERK5 in the VTA was observed in this study. Unpublished data from our laboratory
indicated detection of ERK5 expression using immunohistochemistry and western blot in
the same strain of mice (C57BL/6) used above mentioned strain (Di Benedetto et al.,
2007; Pan et al., 2012). Therefore, this difference could be associated with the primary
ERK5 antibody and/or the technique used for detection. For example, Pan and colleagues
used an ERK5 antibody generated in their laboratory. Moreover, Pan and colleagues
(2012) used immunohistochemistry to detect ERK5 protein and Di Benedetto and
colleagues (2007) used in situ hybridization to detect mRNA. Neither group performed
western blot analysis to confirm the presence of ERK5 protein in adult brain. Using
western blot analysis, several studies have reported the presence of ERK5 in several adult
brain regions such as the hippocampus and cortex/prefrontal/frontal cortex in humans and
rodents (Yoon et al., 2005, Liu et al., 2006, Dwivedi et al., 2007). Our findings suggest
that while total ERK 1, 2, and 5 and phosphorylated ERK 1 and 2 either remain
unchanged or increase with age in the SN, STR, and VTA, ERK5 phosphorylation
decreases with age in the SN and STR. Moreover, inhibition of ERK5 phosphorylation by
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BIX02189 reduced the survival of cultured DA neurons with little effect of inhibition of
ERK 1 and 2. The function and viability of dopaminergic neurons depend on the
availability of neurotrophic factors and subsequent activation of survival signaling
(Lindgren et al., 2008; Pascual et al, 2008; Kim et al., 2011; Hidalgo-Figueroa et al.,
2012). This study highlights the importance of ERK5 signaling in supporting the viability
of dopamine neurons that may play a crucial role in maintaining mature dopaminergic
neurons during adulthood.
ERK 1, 2, and 5 as a function of age: In the present study, with age a decrease in
ERK5 phosphorylation in the SN and STR by old and middle-age, respectively (Figs. 910) was observed. The differences in the decline of p-ERK5 in the SN and STR at
different ages could be regional/localization specific. In the STR, the increased levels of
p-ERK5 at the old age after a significant decline at the middle-age could be associated
with decreased phosphatase activities by the old age. In addition, an increase in ERK2
phosphorylation was observed in the STR with age (Fig. 9). These data suggest the
possibility that cross-talk between these signaling pathways might occurs in the STR such
that an increase p-ERK2 expression occurs to compensate for the decrease in p-ERK5.
Evidence for cross-talk between the ERK1, 2, and 5 pathways has been previously
suggested (Mody et al., 2001; Barros and Marshall, 2005). For example, pharmacological
inhibition of ERK1 and 2 phosphorylation leads to a sustained activation of MEK5 and
ERK5 following growth factor stimulation in HeLa cells (Mody et al., 2001).
Role of ERK5 in the survival of DA neurons: Previously, we have reported that
ERK1, 2, and 5 are important for the basal survival of MN9D cells (Cavanaugh et al.,
2006). However, this phenomenon had not been tested previously in primary DA
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neuronal cultures due to the lack of specific pharmacological inhibitors of the
MEK5/ERK5 pathway. The development of these specific inhibitors, such as BIX02189,
has allowed comparison of the roles of ERK1/2 and ERK5 isoforms in the basal survival
of primary dissociated SN and VTA cultures. Using BIX02189 as a specific inhibitor of
the upstream ERK5 kinase, MEK5, we observed a significant loss of DA neurons, total
cells, and the number of DA neurons as a percentage of the total cells starting at DIV 2 in
the SN and VTA cultures (Figs. 13-15). In contrast, U0126, an inhibitor of ERK1/2
phosphorylation had no such effect at DIV 2 in the SN and VTA cultures (Figs. 13-15).
Similarly, in SH-SY5Y cells, cell viability significantly decreased following treatment
with BIX02189, but not U0126 (Fig. 16). However, following U0126 treatment there is a
significant decline in the DA neurons and total cells at later time points (DIV 4, 6, and 8)
in the VTA culture (Fig. 14). Although not significant, the percentage loss of DA neurons
and total cells in the SN culture were similar to the VTA culture following U0126
treatment at DIV 4, 6 and 8. These data suggest that a loss of ERK1/2 signaling during
early DIV results in an increased vulnerability of SN and VTA DA neurons and other
cells at later time points. However, the number of DA neurons as a ratio of total cells is
not decreased in these same cultures at any time point following U0126 treatment (Fig.
15). The VTA DA neurons have shown to be more resistant to cell death in vivo and in
vitro experiment models (Okamura et al., 1995; Ding et al., 2004) and PD (Uhl et al.,
1985; German et al., 1989) as compared to the SN DA neurons. However, blocking the
ERK5 signaling resulted in approximately equal percentages of DA neuronal-death;
indicating that ERK5 is necessary for the basal survival of DA neurons, in both, the SN
and VTA. These results are in accordance with a previous study in which targeted
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deletion of ERK5 in the developing nervous system reduced the density of dopaminergic
neurons in the olfactory bulb (Zou et al., 2012).
Possible relation to neurotrophic factors: Loss of motor functions and PD are
associated with an age-related loss of nigral DA neurons (Eriksen et al., 2009; Fearnley
and Lees, 1991; Fox et al., 2001; Morgan et al., 1987) and/or dysfunction in the
nigrostriatal dopaminergic pathways (Carlsson and Winblad 1976; McGeer et al., 1977;
Irwin et al. 1994; Gerhardt et al., 1995; Yurek et al., 1998; Yue et al., 2012). These DA
neuronal impairments may be associated with the age-related decline in ERK5 activation
in the SN (DA neuronal cell-body containing region) as observed in the present study.
Neurotrophic factors (NTFs) essential for DA neuron survival, including glial cell linederived neurotrophic factor (GDNF), brain derived neurotrophic factor (BDNF), nerve
growth factor (NGF) and neuregulin (NRG), have been shown to activate the ERK5
pathway (Carlsson et al., 2011; Cavanaugh et al., 2001; Dickerson, 2010; Esparis-Ogando
et al., 2002; Fox et al., 2001; Hayashi et al., 2001; Obara et al., 2009). Moreover, a
critical role for ERK5 in NTF-induced survival of immature cortical, cerebellar, dorsal
root ganglia, and superior cervical ganglion neurons has been reported (Watson et al.,
2001; Liu et al., 2003; Shalizi et al., 2003; Finegan et al., 2009). Age-related declines in
GDNF protein and GDNF and NRG receptors (GFR α-1 and ErbB4, respectively) have
been noted in dopaminergic brain regions (Yurek and Fletcher-Turner, 2001; Dickerson
et al., 2009; Pruett and Salvatore, 2010) and several NTFs are particularly low in the SN
of patients with Parkinson’s disease (Jenner and Olanow, 1998; Mogi et al., 1999; Siegel
and Chauhan, 2000).
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These observations, along with our current data, suggest that age-associated
declines in nigral DA neurons (Morgan et al., 1987; Fearnley and Lees, 1991; Fox et al.,
2001; Eriksen et al., 2009) and motor functions (Irwin et al., 1994; Bennett et al., 1996;
Boger et al., 2006; Allen et al., 2011; Yue et al., 2012) could be a consequence of
decreased ERK5 activation resulting from reduced NTF signaling. Moreover, inhibition
of the ERK5 pathway has been shown to reduce GDNF mRNA and protein levels in
some cells (Obara et al., 2011), suggesting a feedback loop in which MEK5-ERK5
signaling is further decreased.
In conclusion, we present evidence for age-related changes in total and
phosphorylated ERK1, 2, and 5 in DA-rich brain regions during normal aging. The
expression and activation changes in ERK1, 2, and 5 with aging appears to be different in
different dopaminergic brain regions, possibly, indicating their specific role, which need
to be elucidated. Further, we have elucidated distinct roles of ERK1, 2, and 5 in the basal
survival of DA neurons and total cells in SN and VTA primary cultures. As our data
suggest that ERK5 activation is essential for the survival of dopaminergic neurons, the
use of NTFs that activate ERK5 could be a viable therapeutic option to decrease DA
neuronal vulnerability and, thereby, reduce age-related motor deficits and the risk of PD.
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Chapter 3: Postnatal developmental changes in ERK’s protein expression and
activation.
3.1

Rationale:
Early development of dopaminergic midbrain areas, such as SN and VTA and

their dopaminergic inputs into STR are precisely controlled by numerous factors,
including cellular signaling pathways and transcription factors (Ries et al., 2009). Toxic
or harmful exposure to these brain regions during prenatal or postnatal development
could alter cellular signaling pathways and lead to deformation of the dopaminergic
circuit, resulting in neurodegenerative and neuropsychiatric disorders early or later in life.
Hence, elucidating changes in cellular signaling pathways that might be occurring during
postnatal development of dopaminergic brain regions such as SN, VTA, and STR, will
facilitate the understanding of dopamine neuronal dysfunction during disabling
neurologic and psychiatric diseases. Recently, we have shown that blocking the ERK
signaling pathways in primary dopaminergic neurons using specific inhibitors as early as
day in vitro (DIV) 0 resulted into significant loss of viability at DIV 2, 4, 6, and 8
(Chapter 2). Moreover, previous studies have shown that ERK5 levels are highest during
early prenatal development (Liu et al., 2003, 2006). In contrast to ERK5, low expression
of ERK1 and ERK2 has been observed during early development of the nervous system
(brain and spinal cord; Boulton et al., 1991; Liu et al., 2003) and the expression of ERK1
and 2 increases during postnatal development (Boulton et al., 1991). Together these data
suggest that ERK pathways are necessary for basal survival of dopaminergic neurons
during early time points and may play crucial role in the development of dopaminergic
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brain regions. However, no research has studied postnatal developmental changes in
these ERK kinases in dopaminergic brain regions, such as SN, VTA, and STR.
3.2

Hypothesis:

ERK5 activation decreases and ERK1/2 activation increases with postnatal development
in dopaminergic brain regions.
3.3

Materials and Methods

3.3.1

Animals
Time pregnant and adult Sprague-Dawley rats (Charles River) were adapted to a

12:12 h light:dark cycle and provided with water and Purina Rat Chow ad libitum. All
procedures were conducted in accordance with the guidelines for the NIH Care and Use
of Laboratory Animals and approved by the University of Pittsburgh Institutional Animal
Care and Use Committee (IACUC).

Rats from different post developmental stages

(postnatal days 0, 7, 10, 14 and adult, n = 3) were used.
3.3.2

Materials and tissue preparation
The SN, STR, and VTA tissues were isolated from pups brain at day 0, 7, 10 and

14 and adult brain at 0 °C on ice, and frozen using dry ice. Later tissues were stored at 80 °C until analysis. Tissues were homogenized as shown in lysis buffer as described in
Chapter 2 (2.3.2 section).
3.3.3 Western blot analysis
Western blot analysis was performed as described in Chapter 2. Antibodies included
rabbit anti-phospho-ERK1/2 (Dilution – 1:1000, Cat. No. 9101, Cell Signaling,), mouse
anti-total ERK1/2 (Dilution – 1:2000, Cat. No. 9107, Cell Signaling) and rabbit anti-total
ERK5 (Dilution – 1:1,000, Cat. No. 3372, Cell Signaling). Mouse anti-α-Tubulin
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(Dilution – 1:10,000, Cat. No. T5168, Sigma–Aldrich) was used as a loading control. The
secondary antibodies used were goat anti-rabbit (Dilution – 1: 20,000, Cat. No. 92668021, Licor Biosciences) and goat anti-mouse (Dilution – 1: 20,000, Cat. No. 92632210, Licor Biosciences).
3.3.4 Statistical Analysis
GraphPad Prism 5 Software (San Diego, CA) was used for statistical analysis.
Data are expressed as mean ± SEM. Statistical comparison was performed using a oneway analysis of variance (ANOVA) followed by post hoc Dunnet's test. Statistical
significance was defined at p < 0.05.
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3.4

Results:

3.4.1 ERK5 and ERK1/2 are differentially regulated in the SN during postnatal
brain development.
ERK5 and p-ERK5 expression levels decreased during postnatal development in
the SN with significant decline of ERK5 at PND10 and decline in p-ERK5 starting at
PND10 as compared to PND0 (Fig. 17). The amount of ERK5 activation (i.e. pERK5/ERK5) decreased significantly starting at PND14 as compared to PND0 (Fig. 17).
A peak and significant increase in p-ERK1 and p-ERK2 expression levels was observed
at PND7, followed by decline at PND10 and PND14 to the level of adult age (Fig. 17).
Similar to p-ERK1 and p-ERK2 levels, the amount of ERK1 and ERK2 activation (i.e. pERK1/ERK1 and p-ERK2/ERK2) increased significantly at PND7, followed by decline
at PND10 and PND14 to the degree of adult age (Fig. 17). Interestingly, as ERK5
expression declines with postnatal development, a trend increase in ERK1 and a
significant increase in ERK2 are observed with the highest expression levels observed at
adult age (Fig. 17).
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Figure 17: Expression of total and phosphorylated ERK1, ERK2, and ERK5 in the
substantia nigra (SN) during postnatal brain development
A) Levels of total and phosphorylated ERK1, ERK2, and ERK5 in SN were examined by
immunoblotting using equal amount of protein (60 µg/lane) isolated from rat brain at
various ages postnatal (PND0 - PND14) and from adult rat brain. Phosphorylation of
ERK5 is indicated by an electrophoretic mobility shift of the ERK5 band.
B) Quantification of the immunoblots using Licor Odyssey software. The values are
calculated using the integrated intensity. Protein expression was standardized to the
intensity of α-Tubulin and total protein. n = 3 for each age. Data are expressed as mean ±
SEM.* p < 0.05, ** p < 0.01 and *** p < 0.001 indicates a difference compared to the
PND0.
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3.4.2 ERK5, ERK1 and ERK2 are differentially regulated in the VTA during
postnatal brain development.
ERK5 and p-ERK5 expression levels decreased with postnatal development in the
VTA with a significant decrease in ERK5 expression by adult age and p-ERK5 starting at
PND14 as compared to PND0 (Fig. 18). The amount of ERK5 activation (i.e.

p-

ERK5/ERK5) decreased significantly starting at PND14 as compared to PND0 (Fig. 18),
similar to p-ERK5 levels. A biphasic alteration in p-ERK1 and p-ERK2 expression
levels was observed during postnatal development in the VTA such that increases in pERK1 and p-ERK2 levels are observed at PND7 and PND14 as compared to PND0 (Fig.
18). The amount of ERK1 activation (i.e. p-ERK1/ERK1) was significantly increased at
PND7 and PND14, while the amount of ERK2 activation (i.e. p-ERK2/ERK2) was
significantly high at PND7 only as compared to PND0 (Fig. 18). Interestingly, while
ERK5 expression decreases with postnatal development, a trend increase in ERK1 and in
ERK2 is observed with the highest expression levels observed at adult age (Fig. 18).
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Figure 18: Expression of total and phosphorylated ERK1, ERK2, and ERK5 in the
ventral tegmental area (VTA) during postnatal brain development
A) Levels of total and phosphorylated ERK1, ERK2, and ERK5 in VTA were examined
by immunoblotting using equal amount of protein (60 µg/lane) isolated from rat brain at
various ages postnatal (PND0-PND14) and from adult rat brain. Phosphorylation of
ERK5 is indicated by an electrophoretic mobility shift of the ERK5 band.
B) Quantification of the immunoblots using Licor Odyssey software. The values are
calculated using the integrated intensity. Protein expression was standardized to the
intensity of α-Tubulin and total protein. n = 3 for each age. Data are expressed as mean ±
SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 indicates a difference compared to the
PND0.
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3.4.3 ERK5, ERK1 and ERK2 are differentially regulated in the STR during
postnatal brain development.
ERK5 and p-ERK5 expression levels significantly decreased with postnatal
development in the STR starting at PND7 and continuing to adult age as compared to
PND0 (Fig. 19). Similar to ERK5 and p-ERK5 expression levels, a significant decrease in
p-ERK1 and p-ERK2 expression levels was observed with postnatal development at
PND7 through adult age as compared to PND0 (Fig. 19). The amount of ERK1 and
ERK2 activation (i.e. p-ERK1/ERK1 and p-ERK2/ERK2) is also significantly decreased
as compared to PND0 (Fig. 19), similar to p-ERK1 and p-ERK2 expression levels.
Although declines in phosphorylated ERK1, ERK2, and ERK5 and total ERK5
expressions were noted with postnatal development, a trend increase in ERK1 and a
significant increase in ERK2 were observed with the highest expression observed at adult
age (Fig. 19).
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Figure 19: Expression of total and phosphorylated ERK1, ERK2, and ERK5 in the
striatum (STR) during postnatal brain development
A) Levels of total and phosphorylated ERK1, ERK2, and ERK5 in STR were examined
by immunoblotting using equal amount of protein (60 µg/lane) isolated from rat brain at
various ages postnatal (PND0-PND14) and from adult rat brain. Phosphorylation of
ERK5 is indicated by an electrophoretic mobility shift of the ERK5 band.
B) Quantification of the immunoblots using Licor Odyssey software. The values are
calculated using the integrated intensity. Protein expression was standardized to the
intensity of α-Tubulin and total protein. n = 3 for each age. Data are expressed as mean ±
SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 indicates a difference compared to the
PND0.

90

3.5

Discussion
To examine the MAPKs signaling alterations in the postnatal development of the

SN, VTA, and STR, the protein levels of total (non-phosphorylated) and
phosphorylated/activated ERK1, ERK2, and ERK5 were measured at different postnatal
ages. In contrast to previous studies in which no ERK5 mRNA or protein was detected in
the dopaminergic brain regions of the adult mouse or the brain as a whole (Di Benedetto
et al., 2007; Pan et al., 2012), both total and phosphorylated ERK5 protein were detected
in each of the aforementioned brain regions in the postnatal and adult brain (Figs. 17-19).
The expression levels of activated ERK1 (i.e. p-ERK1) and ERK2 (i.e. p-ERK2)
in the dopaminergic brain regions, SN and VTA, changed considerably during postnatal
development, with a peak at PND7 in SN and biphasic peaks at PND7 and PND14 in
VTA (Figs. 17-18). In contrast, in the STR, the expression of p-ERK1 and p-ERK2 was
significantly lower beginning at PND7 until adult age relative to PND0 (Fig. 19).
However, with postnatal development an increase in total ERK1 and/or ERK2 expression
are observed in all dopaminergic brain regions. This is in accordance with an observance
made by Boulton and colleagues (1991), indicating lower expression of ERK1 and ERK2
in the nervous system (brain and spinal cord) during embryonic development and
increase in their expression with postnatal development. ERK5 and p-ERK5 expression
were highest at early postnatal development days and gradually subsided as the brain
matured. This is in accordance with data reported by Liu and colleagues (2003, 2006) that
showed highest expression of ERK5 and/or p-ERK5 in cortex and whole brain during
early embryonic development but declined as the brain matures with postnatal
development. Overall, with a decline in total and phosphorylated ERK5 a concurrent
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increase in total ERK1 and/or ERK2 is observed in the SN, STR and VTA regions with
postnatal development (Figs. 17-19). This pattern of expression suggests that ERK5 may
be necessary for early development, and ERK1 and/or ERK2 for later postnatal
development of nigrostriatal and mesolimbic system. As shown in Chapter 2 (Figs. 1315) inhibition of ERK5 activation in PND0 primary dopamine neuronal in vitro cultures
from SN and VTA resulted in significant losses of TH + dopamine neurons at early days
in vitro (Chapter 1); while inhibition of ERK1/2 activation did not lead to a significant
loss of TH+ dopamine neurons until later time points. Together these data indicate that
ERK5 may be necessary for dopaminergic neurons survival during early pre- and
postnatal SN and VTA development, while ERK1/2 is necessary for postnatal survival
later in development and aging.
In SN, VTA, and STR tissues, the alterations in ERK kinases (Figs. 17-19) during
postnatal development could be contributing to several processes that occur during the
development of rat nigrostriatal and mesolimbic systems, such as maintenance of
neuronal viability, integrity of already differentiated neurons, DA neuronal natural cell
death event in the SNc, differentiation of DA terminals in the STR, increases in TH
activity, and increases in synapse density in STR and SNc (Burke, 2003). Changes in the
levels of neurotrophic factors, such as GDNF, with postnatal development have been
noted in STR and SN (Cho et al., 2003). For instance, after birth or during early postnatal
development, GDNF mRNA and protein levels are high in the STR and SN and decrease
with age (Blum et al., 1995; Lopez-Martin et al., 1999; Cho et al., 2003). These
alterations in ERK signaling could be the result of changes in physiological levels of
these neurotrophic factors, which are required for survival and postnatal development to
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of SN DA neurons (Burke, 2003; Oo et al., 2009). These neurotrophic factors been shown
to activate these ERKs (Cavanaugh et al., 2001; Hayashi et al., 2001; Obara et al., 2011).
The neurophysiological role of ERKs changes during first two weeks of postnatal
development is not clear at this time. Hence, the use of specific MEK inhibitors to block
ERK1, ERK2, and/or ERK5 signaling during early postnatal development would allow
determination of their specific role in development of nigrostriatal and mesolimbic
systems.
In conclusion, with postnatal development differences in expression pattern of
ERK1, ERK2, and ERK5 were observed in all the three-dopaminergic brain regions.
Similar to previously reports, higher expression of ERK5 was observed at early PND that
declined with postnatal development, while lower expression of ERK1/2 was observed at
early PND that increased the postnatal development. An understanding of the differences
in expression patterns of the ERKs during postnatal development may provide significant
insights into their role in the development of dopaminergic system.
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Chapter 4: GDNF and DNSP-11-mediated protection against oxidative-stress
induced toxicity.
4.1

Rationale
Glial cell line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor

that may be a promising therapeutic agent for the treatment of Parkinson’s disease (PD).
The ability of GDNF to protect dopamine neurons against several neurotoxins, including
MPTP and 6-hydroxydopamine (6-OHDA)(Kearns and Gash, 1995; Kearns et al., 1997;
Hoffer et al., 1994; Hou et al., 1996) and to improve parkinsonian symptoms (Gash et al.,
1996; Grondin et al., 2002; Smith and Cass, 2007), lead GDNF into clinical trials.
However, due to concerns related to its delivery problem, inter-trial variability among
clinical studies, development of safety concerns due to detection of antibodies against
GDNF in 10% of the patients undergoing the trial, and observed toxicity in the
cerebellum of non-human primates caused the discontinuation of the trial (Gill et al.,
2003; Slevin et al., 2005, 2006; Lang et al., 2006; Salvatore et al., 2006). Despite these
setbacks, GDNF was effective in relieving PD symptoms (Gill et al, 2003; Slevin et al.,
2005). Due to this effectiveness of GDNF, a search for a new neurotrophic factor, peptide
or molecule that has similar beneficial neuroprotective effects is ongoing. Recently
dopamine neuron stimulating peptide-11 (DNSP-11), a pro-peptide molecule of GDNF,
has been made and shows promise in protecting dopaminergic neurons against neuronal
toxicity (Bradley et al., 2010; Sonne, 2013). For example, DNSP-11 restored
dopaminergic activity in a 6-OHDA lesion rat model (Bradley et al., 2010; Fuqua, 2010;
Sonne, 2013). Moreover, DNSP-11 has been shown to prevent dopaminergic cell loss
following exposure to several other neurotoxins (Bradley et al., 2010, 2013). However,
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the molecular mechanisms of DNSP-11-medicated neuroprotection are still unclear.
Hence, the objective of this study was to determine whether DNSP-11 protects human
dopaminergic neuroblastoma SH-SY5Y cells against neurotoxin-induced toxicity and to
elucidate the cellular signaling mechanisms that may be involved in DNSP-11-mediated
protection.
4.2

Hypothesis

GDNF and DNSP-11 inhibit neurotoxin-mediated toxicity in human dopaminergic
neuroblastoma SH-SY5Y cell line via activation of the ERK signaling pathways.
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4.3

Materials and Methods

4.3.1

Animals
Adult (3-4 months) Fisher 344 rats (Harlan, Indianapolis, IN) were adapted to a

12:12 h light: dark cycle and provided with water and Purina Rat Chow ad libitum. All
procedures were conducted in accordance with the guidelines for the NIH Care and Use
of Laboratory Animals and approved by the Duquesne University Institutional Animal
Care and Use Committee (IACUC).
4.3.2

Western blot analysis
Western blot analysis was performed as described in chapter 2. Cell lysates and

tissue lysates were centrifuged at 11,000 rpm for 30 min at 4 ºC and the supernatant was
collected and stored at -80 ºC. For cell lysates, 30 μg and for tissue lysates, 60 μg of
protein was loaded on an 8% SDS-PAGE gel. Antibodies included rabbit anti-phosphoERK1/2 (Dilution – 1:1000, Cat. No. 9101, Cell Signaling), mouse anti-total ERK1/2
(Dilution – 1:2000, Cat. No. 9107, Cell Signaling), anti-phospho-ERK5 (Cat. No. 3371,
Cell Signaling) and rabbit anti-total ERK5 (Dilution – 1:1,000, Cat. No. E1523, SigmaAldrich). Mouse anti-α-Tubulin (Dilution – 1:10,000, Cat. No. T5168, Sigma–Aldrich)
was used as a loading control. The secondary antibodies used were goat anti-rabbit
(Dilution – 1:20,000, Cat. No. 926-68021, Licor Biosciences) and goat anti-mouse
(Dilution – 1:20,000, Cat. No. 926-32210, Licor Biosciences).
4.3.3

SH-SY5Y cells culture and treatment
Cells were cultured as described in Chapter 2 (2.3.7 section).
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4.3.4

6-Hydroxydopamine treatment
For viability experiments, SH-SY5Y cells were plated at 15,000 cells per well in

triplicate in 96-well plates (Cat. No. 3603, Black plate with clear bottom, Corning
Incorporated), and treatments were performed 48 h after plating.

On the day of

treatment, serum-containing media was withdrawn from the wells and replaced with
serum-free media. The cells were serum starved for 6 h and treated with freshly prepared
6-OHDA (6-Hydroxydopamine hydrochloride, Cat. No. H4381, Sigma-Aldrich) solution.
The

6-OHDA

solution was

prepared

in vehicle

containing

metal chelator

diethylenetriaminepentaacetic acid (DETAPAC; 10 mM; Cat. No. D6518, SigmaAldrich) and ascorbic acid (0.15%, Cat. No. A61-100, Fisher Scientific, Pittsburgh, PA)
that is flushed with argon for 10 min while the solution was sitting on ice. Argon flush
allowed minimization of the extracellular oxidation of 6-OHDA. First, 10 mM stock
solution of 6-OHDA was prepared in above vehicle, followed by 1 mM solution in
media, which was added to the wells containing media to give 100 µM of treatment.
Unless otherwise noted, treatment with 6-OHDA was carried out for 30 min. After 30
min, the 6-OHDA-containing media was removed to halt the 6-OHDA treatment and the
cells were incubated in fresh standard serum-free media for 24 h (for CTG viability
assay) and 6 h (for caspase 3/7 activity assay). The effects of 6-OHDA were always
compared with the effects of its vehicle.
4.3.5

GDNF and DNSP-11 treatment
For viability and caspase 3/7 activity experiments, SH-SY5Y cells were plated at

15,000 cells per well in triplicate in 96-well plates (Cat. No. 3603, Black plate with clear
bottom), and treatments were performed 48 h after plating. On the day of treatment,
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serum containing media was withdrawn from the wells and replaced with media without
serum. The cells were serum starved for 6 h. After 6 h of serum starvation, cells were pretreated with GDNF (Cat. No. G240, Alomone Labs, Jerusalem, Israel) or DNSP-11(Cat.
No. D8571, Sigma-Aldrich) for 1 h followed by 30 min treatment with 6-OHDA. GDNF
or DNSP-11 was present during treatment with 6-OHDA. After 30 min of 6-OHDA
treatment, the GDNF or DNSP-11 and 6-OHDA-containing media is removed and the
cells are incubated with fresh standard serum-free media containing GDNF or DNSP-11
for 24 h (for CTG viability assay) and 6 h (for caspase 3/7 activity assay). The protective
effects of GDNF and DNSP-11 in presence of 6-OHDA were always compared with the
effects of 6-OHDA alone.
4.3.6

CellTiter-Glo® Luminescent Cell Viability Assay
See Chapter 2 (2.3.8).

4.3.7

Caspase-Glo® 3/7 Activity Assay
The activity of caspase-3 and caspase-7 was detected in 96-well (Cat. No. 3603,

Black plate with clear bottom, Corning Incorporated) format using the Caspase-Glo® 3/7
Assay (Cat. No. G8091, Promega Inc., Madison, WI). This assay is a luminescent assay
that measures caspase-3 and -7 activities in purified enzyme preparations or cultures of
adherent or suspension cells. The assay provides a proluminescent caspase-3/7 substrate,
which contains the tetra peptide sequence DEVD. This substrate is cleaved by caspase3/7 to release aminoluciferin, a substrate of luciferase used in the production of light.
Briefly, 100 µl of the Caspase-Glo 3/7 reagent were added to each well containing
100 µl of media and then the contents of wells were gently mixed using a plate shaker at
300-500 rpm for 30 seconds. The plate was then incubated at room temperature for 1 h.
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Luminescence was measured on a microplate reader (Victor3 1420 multilabel counter,
PerkinElmer, MA).

Figure 20: Caspase-3/7 cleavage of the luminogenic substrate containing
the DEVD sequence
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4.3.8

Intrastriatal infusion of DNSP-11
Animals (n = 5 /group) were anesthetized with isoflorane and placed in a Kopf

stereotaxic apparatus (David Kopf Instruments, Tujunga, CA). DNSP-11 (Cat. No.
D8571, Sigma-Aldrich) was infused unilaterally (30 µg) into the STR using a Hamilton
syringe (10 µl, 701SN 30/2”/3, Cat. No. 80308, Hamilton Company, Reno, NV) in
accordance with a stereotaxic rat brain atlas (Paxinos and Watson, 1997). DNSP-11 was
dissolved in pH 5 Citrate Buffer (150 mM NaCl and 10 mM Sodium Citrate). The
following stereotaxic coordinates from bregma were used to deliver the infusion
solutions: anterior posterior (AP): + 0.3 mm, medial lateral (ML): + 2.7 mm, dorsal
ventral (DV): - 5.6 mm. An infusion rate of 0.5 μl/minute over 12 min was controlled by
the Stoelting Quintessential Injector (Cat. No. 53311, Stoelting Co., Wood Dale, IL) to
deliver 6 μl of the DNSP-11 or citrate vehicle buffer treatment solution to the infusion
site in the STR. In order to allow DNSP-11 or citrate vehicle buffer to diffusion into the
tissue and minimize leakage while syringe withdrawal, the syringe was left in place for 5
min after the infusion was terminated. Control animals received injections of citrate
vehicle buffer) only. Animals were killed through decapitation and brain tissue, STR and
SN, were isolated at different time points (2 h, 6 h, 24 h and 7 days) post DNSP-11 or
vehicle infusion.
4.3.9

Statistical Analysis
GraphPad Prism 5 Software (San Diego, CA) was used for statistical analysis.

Data are expressed as mean ± SEM. For viability studies, statistical significance was
determined by two-way ANOVA followed by the Bonferroni post hoc test. For DNSP-
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11 infusion study, statistical significance was determined using a two-tailed Student's ttest for unpaired data. Statistical significance was defined at p < 0.05.
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4.4

Results

4.4.1

6-OHDA treatment causes concentration-dependent toxicity in SH-SY5Y
cells.
Exposure to 6-OHDA for 30 min produced a concentration-dependent decrease in

the viability of SH-SY5Y cells measured at 24 h following 6-OHDA using a CTG assay
(Fig. 21). The percentage loss of viability with 50, 100, and 200 µM 6-OHDA treatment
was 13, 50, and 66%, respectively (Fig. 21). For all subsequent experiments, we used 100
µM 6-OHDA concentrations to detect changes in cell viability.
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Figure 21: 6-OHDA-induced toxicity in SH-SY5Y cells
SH-SY5Y cells were treated with 6-OHDA (0, 50,100 and 200 µM) for 30 min, the
media containing 6-OHDA was replaced with fresh media, and a CTG viability assay was
performed 24 h post 6-OHDA treatment. Data are expressed as mean ± SEM. The data
are averages of triplicates from 6-9 independent experiments. Statistical significance was
determined by one-way ANOVA followed by post hoc Dunnet's test. * p < 0.05, ** p <
0.01, and *** p < 0.001 indicates a difference compared to the vehicle control (6OHDA; 0 µM).
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4.4.2 Pretreatment with GDNF or DNSP-11 does not protect SH-SY5Y cells
against 6-OHDA toxicity.
SH-SY5Y cells were treated with GDNF or DNSP-11 and 6-OHDA as described
in the methods section. Pretreatment with GDNF (50 and 100 ng/ml) or DNSP-11 (1, 10,
100, 500 and 1000 ng/ml) did not protect SH-SY5Y cells against 6-OHDA-induced
toxicity (Figs. 22A and 22B).
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Figure 22: GDNF and DNSP-11 did not protected SH-SY5Y cells against 6-OHDAinduced toxicity
SH-SY5Y cells were pretreated for 1 h with A) GDNF (0, 10 and 50 ng/ml) and B)
DNSP-11 (0,1,10,100,500 and 1000 ng/ml) followed by 6-OHDA (100 µM; 30 min)
treatment. The media containing 6-OHDA was removed, replaced with fresh media
containing GDNF or DNSP-11, and a CTG viability assay was performed 24 h post 6OHDA treatment. Data are expressed as mean ± SEM. The data are averaged of
triplicates from 3 independent experiments. Statistical significance was determined by
two-way ANOVA followed by the Bonferroni post hoc test. **** p < 0.0001 indicates a
difference compared to the vehicle control (6-OHDA; 0 µM).
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4.4.3

6-OHDA treatment increases Caspase-3/7 activity in SH-SY5Y cells.
Treatment with 6-OHDA was performed as described in the method section. A

significant increase in caspase-3/7 activity was observed following 6-OHDA treatment
for 6 h (Fig. 23). Caspase-3/7 activity declined in 6-OHDA (200 µM) treatment to the
level of control (Fig. 23).
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Figure 23: 6-OHDA- induced increase in caspase-3/7 activity
SH-SY5Y cells were treated with 6-OHDA (0, 50,100 and 200 µM; 30 min) for 30 min,
the media containing 6-OHDA was replaced with fresh media, and a caspase-3/7 assay
was performed 6 h post 6-OHDA treatment. Data are expressed as mean ± SEM. The
data are averaged of triplicates from 3-6 independent experiments. Statistical significance
was determined by one-way ANOVA followed by post hoc Dunnet's test. *** p < 0.001
indicates a difference compared to the vehicle control (6-OHDA; 0 µM).
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4.4.4 GDNF or DNSP-11 pretreatment decreases 6-OHDA–induced caspase-3/7
activity in SH-SY5Y cells.
To investigate whether GDNF or DNSP-11 are able to prevent early apoptotic
events induced by 6-OHDA in SH-SY5Y cells, caspase-3/7 activity was measured.
Pretreatment with GDNF or DNSP-11 significantly inhibited 6-OHDA-induced caspase3/7 activation (Fig. 24). GDNF (50 ng/ml) produced a significant reduction in the 6OHDA-induced caspase-3/7 activity (Fig. 24). A significant decline in 6-OHDA-induced
caspase-3/7 activity was also observed with 500 and 1000 ng/ml doses of DNSP-11 (Fig.
24).The highest reduction in 6-OHDA-induced caspase-3/7 activity was observed with
GDNF (50 ng/ml; 225%) as compared to 135 % and 134% reduction by 500 and 1000
ng/ml DNSP-11, respectively (Fig. 24).
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Figure 24: GDNF and DNSP-11 reduced the 6-OHDA-induced increase in caspase3/7 activity
SH-SY5Y cells were pretreated for 1 h with A) GDNF (0, 10 and 50 ng/ml) and B)
DNSP-11 (0,1,10,100,500 and 1000 ng/ml) followed by 6-OHDA (100 µM; 30 min)
treatment. The media containing 6-OHDA was removed, replaced with fresh media
containing GDNF or DNSP-11, and a caspase-3/7 assay was performed 6 h post 6-OHDA
removal. Data are expressed as mean ± SEM. The data are averaged of triplicates from 3
independent experiments. Statistical significance was determined by two-way ANOVA
followed by the Bonferroni post hoc test. **** p < 0.0001 indicates a difference
compared to the vehicle control (6-OHDA; 0 µM). ## p < 0.05 and #### p < 0.0001
indicates a difference compared to the vehicle 6-OHDA (100 µM) treatment only.
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4.4.5

GDNF and DNSP-11 activate ERK1/ 2 and ERK5 cellular signaling.
To gain insight into GDNF and DNSP-11-mediated cellular mechanisms that may

play a role in early protection against 6-OHDA toxicity, we investigated GDNF and
DNSP-11-mediated activation of pro-survival cellular signaling. SH-SY5Y cells were
serum starved for 24 h and stimulated with GDNF or DNSP-11 for different time points.
Treatment of SH-SY5Y cells with different concentrations of GDNF (10, 50, and
100 ng/ml) increased the phosphorylation of ERK1/2 and ERK5 as compared to no
treatment at 30, 60 and 120 min (Fig. 25A). Highest activation of these pathways was
observed with 50 and 100 ng/ml doses of GDNF for all the time points (Fig. 25A).
Hence, to determine the time course of ERK1/2 and ERK5 activation by GDNF, we used
the 50 ng/ml dose of GDNF. GDNF (50 ng/ml) increased ERK1 and ERK2, and ERK5
phosphorylation at the earliest measured time point (Fig. 25B). The activation of ERK1/2
and ERK5 was sustained until 2 h and declined by baseline by 24 h (Fig. 25B).
Similar to GDNF, DNSP-11 (1 µg/ml) activated ERK1/2 and ERK5 signaling
(Fig. 25C). Increased ERK5 phosphorylation was observed starting at 5 min and was
sustained up to 60 min (Fig. 25C). Interestingly, DNSP-11 mediated activation of
ERK1/2 was more transient than that of ERK5 with maximum activation at 15 min. (Fig.
25C).
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Figure 25: GDNF and DNSP-11 activate ERK1, ERK2 and ERK5 cellular signaling
SH-SY5Y cells were serum starved for 24 h and treated with A) GDNF (0, 10, 50 and
100 ng/ml), B) GDNF (50 ng/ml) and C) DNSP-11 (1 µg/ml) for different time points.
Cell lysates were collected and immunoblot analysis was performed to measure protein
levels. Phosphorylation of ERK5 is indicated by an electrophoretic mobility shift of the
ERK5 band.
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4.4.6 Intrastriatal infusion of DNSP-11 modulates ERK signaling pathways and
TH protein expression in the STR and SN.
To gain insight into the effect of DNSP-11 on the ERKs cellular signaling in the
dopaminergic regions in vivo, DNSP-11 was injected into the striatum. At different time
intervals after DNSP-11 infusion, striatum and substantia nigra tissues were isolated and
western blot analysis was performed to detect the modulation of ERKs and TH protein
expression.
In striatum
There was no significant difference in basal ERK1, 2, and 5 levels in the STR
from DNSP-11 treated animals versus control treated animals (Fig. 26). ERK5
phosphorylation was not detected in this tissue region neither in control nor DNSP-11
treatment group. Intrastriatal infusion of DNSP-11 did not activate ERK1 at any time
point, while a significant decrease in ERK2 phosphorylation (33%) was observed at 6 h
as compared to control (Fig. 26). A significant increase (42%) in TH expression with
DNSP-11 treatment was observed at 7 day post DNSP-11 treatment (Fig. 28).
In substantia nigraThere was no significant difference in basal and phosphorylated ERK1, 2, and 5
levels in the SN from DNSP-11 treated animals versus control treated animals (Fig. 27).
However, there was a trend towards an increase in basal ERK5 (33%) and
phosphorylated ERK1 (32%) levels at 7 days and phosphorylated ERK2 (42%) at 2 h
post DNSP-11 treatment (Fig. 27). ERK5 phosphorylation was not detected in this tissue
region neither in control nor DNSP-11 treatment group. A decline in TH expression
(33%) with DNSP-11 treatment was observed at 2 h followed by 32% increase at 6 h post
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DNSP-11 treatment (Fig. 28). At 24 h and 7 days following DNSP-11 infusion, no
difference was observed in TH expression levels between DNSP-11 and control treated
animals (Fig. 28).
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Figure 26: Modulation of ERK1, ERK2, and ERK5 signaling by intrastriatal
infusion of DNSP-11 in the STR
DNSP-11 (30 µg) was infused into STR. Two hours, 6 h, 24 h and 7 days post infusion,
STR and SN tissues were isolated.
A) Immunoblot analysis of total and phosphorylated ERK1, ERK2, and ERK5 in the
STR.
B) Quantification of the immunoblots was performed using Licor Odyssey software. The
values are calculated using the integrated intensity. Protein expression was standardized
to the intensity of α-Tubulin. n = 5 for each age. Data are expressed as mean ± SEM. ^ p
< 0.05 indicates a difference compared to the vehicle control. A two-tailed Student's t-test
for unpaired data was also used for statistical comparisons. 2C - 2 h control; 2D - 2 h
DNSP-11; 6C - 6 h control; 6D - 6 h DNSP-11;
24C - 24 h control; 24D - 24 h DNSP-11; 7C – 7 days control; 7D – 7 days DNSP-11.
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Figure 27: Modulation of ERK1, ERK2, and ERK5 signaling by intrastriatal
infusion of DNSP in the SN
DNSP-11 (30 µg) was infused into STR. Two hours, 6 h, 24 h and 7 days post infusion,
STR and SN tissues were isolated.
A) Immunoblot analysis of total and phosphorylated ERK1, ERK2, and ERK5 in the SN.
B) Quantification of the immunoblots was performed using Licor Odyssey software. The
values are calculated using the integrated intensity. Protein expression was standardized
to the intensity of α-Tubulin. n = 5 for each age. Data are expressed as mean ± SEM. A
two-tailed Student's t-test for unpaired data was also used for statistical comparisons. 2C
- 2 h control; 2D - 2 h DNSP-11; 6C - 6 h control; 6D - 6 h DNSP-11; 24C - 24 h control;
24D - 24 h DNSP-11; 7C – 7 days control; 7D – 7 days DNSP-11.
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Figure 28: Modulation of TH protein expression by intrastriatal infusion of DNSP11 in the STR and SN
DNSP-11 (30 µg) was infused into STR. Two hours, 6 h, 24 h and 7 days post infusion,
STR and SN tissues were isolated. Immunoblot analysis of TH expression in the STR and
SN. Quantification of the immunoblots was performed using Licor Odyssey software.
The values are calculated using the integrated intensity. Protein expression was
standardized to the intensity of α-Tubulin. n = 5 for each age. Data are expressed as mean
± SEM. ^^ p < 0.01 indicates a difference compared to the vehicle control. A two-tailed
Student's t-test for unpaired data was also used for statistical comparisons.
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4.5

Discussion
DNSP-11, an endopeptidase cleavage product from the human GDNF

prosequence, has been shown to possess neurotrophic and neuroprotective properties of
GDNF (Fuqua, 2010; Bradley et al., 2010, Sonne, 2013). For example, DNSP-11 has
been shown to protect dopaminergic cells against neurotoxin-induced toxicity in vitro and
in vivo (Bradley et al., 2010, 2013; Sonne, 2013). More specifically, Bradley and
colleagues (2010) used MN9D cells to study the effect of DNSP-11 pretreatment on 6OHDA-induced toxicity and they found that pretreatment with DNSP-11 significantly
inhibited the 6-OHDA-induced increase in apoptosis and caspase-3 activity (Bradley et
al., 2010).
Another widely used cellular model of dopaminergic neurons is SH-SY5Y cells.
SH-SY5Y cells express many features of DA neurons and are widely used to study
neuroprotective properties of phytochemicals, neurotrophins, and growth factors. Hence,
in the current study the effects of DNSP-11 and GDNF were examined in SH-SY5Y
cells. As seen in figure 20A, 6-OHDA treatment induced a concentration-dependent
decrease in SH-SY5Y cell viability. At 100 µM, 6-OHDA reduced cell viability by
approximately 50% when measured by the CTG assay (Fig. 21). Pretreatment with
GDNF (Fig. 22A) or DNSP-11 (Fig. 22B) did not decrease the 6-OHDA-induced loss of
cell viability when measured at 24 h using the CTG assay. Failure of GDNF to block 6OHDA-induced cell loss has also been observed by others (Kramer et al., 1999, Ding et
al., 2004). For example, Ugarte and colleagues (2003) failed to observe GDNF-mediated
protection against 6-OHDA-induced cell death at 24 h using a trypan blue exclusion
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assay. GDNF was also not able to protect embryonic mesencephalic dopamine neuronal
cultures against 6-OHDA toxicity at time periods greater than 24 h (Kramer et al., 1999).
In contrast to assays that measure generalized cell death, GDNF and DNSP-11
protected against 6-OHDA–induced apoptotic events when assays that detect apoptotic
events, such as nuclear condensation and fragmentation, TUNEL assays, and caspase-3/7
assays were used (Ugarte et al., 2003, Bradley, et al., 2010). These data suggest that
GDNF blocks some, but not all, of the cytotoxic effects of 6-OHDA. Another important
point to be noted from previous studies is that GDNF and DNSP-11 protected against 6OHDA toxicity at early time points (i.e. < 24 h) following 6-OHDA treatment (Bradley et
al., 2010, 2013). Therefore, we determined whether GDNF or DNSP-11 is able to block
early apoptotic signaling events, such as caspase-3/7 activity. Increase in caspase-3/7
activity has been associated with apoptotic cell death. As seen in figure 24, pretreatment
with GDNF or DNSP-11 significantly reduced 6-OHDA-induced caspase-3/7 activity.
GDNF caused a 225% reduction in caspase-3/7 activity versus a 135 % reduction by
DNSP-11 (Fig. 24). This observed decrease in caspase activity with GDNF and DNSP-11
against neurotoxin is in accordance with a study by Bradley and colleagues (2010, 2013).
The ability of GDNF and DNSP-11 to reduce 6-OHDA-induced capase-3/7 activity,
which is an early apoptotic event, while they are unable to provide protection against cell
death at later times (≥ 24 h), could be attributed to 6-OHDA-induced damage to the outer
membrane of mitochondria and various organelles that overcome the early beneficial
effects of GDNF and DNSP-11. Secondly, GDNF and DNSP-11 might have only short
term effects for several reasons. For example, supporting cells, such as glia, may be
required for these agents to provide neuroprotective effects and/or anti-apoptotic cellular
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signaling pathways may only be transiently activated by GDNF and DNSP-11. The
difference in the doses of GDNF and DNSP-11, at which the protective effect is
observed, with respect to reduction in caspase-3/7 activity, could be associated with the
differences in amplification and activation of protective cellular protective mechanisms.
The GDNF-mediated activation of protective cellular signaling through GFRα1/RET
receptor signaling pathway is well studied, whereas, the mode of DNSP-11-mediated
cellular protection is not well studied and it’s under investigation. Differences in the
function of DNSP-11 and GDNF have been already shown (Bradley et al., 2010). No
dose-dependent significant difference in the reduction of 6-OHDA-induced caspase-3/7
activity observed at DNSP-11 (500 and 1000 ng/ml) in the SH-SY5Y. This may be
associated with saturation of protective cellular signaling activation.
To investigate the effect of GDNF and DNSP- on pro-survival signaling
pathways, ERK1, 2, and 5 signaling was examined in the SH-SY5Y cells. ERK1, 2, and 5
were chosen as they have been shown to decrease oxidative stress-induced dopamine
neuronal cell death (Ugarte et al., 2003; Cavanaugh et al., 2006). Treatment of SH-SY5Y
cells with GDNF or DNSP-11 increased the phosphorylation of ERK1, 2, and 5 starting
at early time points (Fig. 25B and 25C). GDNF treatment caused a sustained activation of
ERK1, 2, and 5 (Fig. 25A-25B), while DNSP-11 treatment transiently increased ERK1
and 2 phosphorylation (Fig. 25C). This difference may be associated with differences in
mode of activation of these cellular signaling. As previously mentioned, GDNF acts
through GFRα-/RET receptor mechanism; however, so far DNSP-11 appears to be less
likely act through this receptor mechanism (Bradley et al., 2010) and understanding of
DNSP-11 mode of action is required to address this difference. Similar to GDNF, DNSP-
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11 caused a sustained increase in ERK5 phosphorylation (Fig. 25C). Therefore, the
GDNF and DNSP-11-mediated reduction in oxidative stress-induced caspase-3/7 activity
may be attributed to ERK1, 2, and 5 activation. Activation of ERK signaling has been
shown to prevent apoptosis through suppression of caspase activity either by upregulation
of anti-apoptotic proteins, such as Bcl-2 and Bcl-w, and/or downregulation of apoptotic
proteins, such as Bim (that are present at mitochondrial membrane) (O’Connor et al.,
1998; Ley et al., 2003; Pazyra-Murphy et al., 2009; Roberts et al., 2010; Wang et al.,
2013), thereby, preventing loss of mitochondrial outer membrane potential and release of
cytochrome c, which activates caspases.
DNSP-11 has profound effects in animal models of PD and has been shown to
possess neuroprotective and neurorestorative properties in the nigrostriatal system
(Bradley et al., 2010; Sonne, 2013). A single infusion of the DNSP-11 in the SN led to an
increase in dopamine, DOPAC, and HVA in the STR (Bradley et al., 2010). To
understand the molecular events that are activated by DNSP-11 in vivo, we infused a
single dose of DNSP-11(30 µg) into the STR and examined the effect on ERK signaling
in the nigrostriatal system. In the STR, a significant decline in ERK2 phosphorylation
(33%) was observed at 6 h post DNSP-11 treatment with no change in any other basal or
phosphorylated ERK proteins at any other time points detected (Fig. 26). In the SN, a
trend increase in phosphorylation of ERK1 and 2 was observed (Fig. 27). Additionally,
although not significant, a 42% and 32% rise in TH levels in the STR and SN,
respectively, were observed after DNSP-11 treatment (Fig. 28). The decrease in TH
expression observed at 2 h in SN (Fig. 28) could be associated with increase in
phosphorylated TH form, resulting in decline in basal TH level. To test this hypothesis,
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levels of p-TH need to be analyzed using western blot analysis. As the DNSP-11 was
infused in the striatum, it is possible that retrograde transportation of DNSP-11 from the
STR (dopamine nerve terminal containging region) to the SN (dopamine cell body
containing region) may have occurred to increase ERK1 and 2 phosphorylation and TH
expression. Similar to the current study, modulation of ERK1 and ERK2 activation and
TH levels have been observed in the SN after intrastriatal infusion of neurotrophic
factors, such as GDNF and BDNF (Mufson et al., 1994; Salvatore et al., 2004, Lindgren
et al., 2008, 2012). Retrograde transportation of GDNF from the nerve terminal to cell
body, thereby, activation of cellular signaling in the cell body has been shown to be
associated with receptor machinery, involving GFRα -1 (Coulpier et al., 2004).
Tyrosine hydroxylase has shown to regulate DA bioavailability (Salvatore et al.,
2009). Therefore, the rise in TH expression in the STR may underlie the increase in
striatal dopamine levels observed with DNSP-11 treatment in the previous study by
Bradley and colleagues (2010).
In conclusion, DNSP-11 was not able to protect SH-SY5Y cells against 6-OHDAinduced toxicity, when viability was measeured at 24 h. However, significant reduction in
6-OHDA-induced caspase 3/7 activity was observed with DNSP-11 at early time points.
In SH-SY5Y cells, DNPS-11 treatment leads to increase in ERK1/2, and ERK5
activation. Collectively, the anti-apoptotic properties of DNSP-11 in dopaminergic SHSY5Y cells, along with its ability to modulate ERK1, 2, and TH in dopaminergic brain
regions, in vivo, are analogous to GDNF and suggest that is may be a good therapeutic
candidate for PD.
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Chapter 5: Conclusions and Future directions
With normal aging dysfunctioning in dopaminergic system, especially nigrostrital
system has been observed, that have shown to be resulted in motor deficits, parkinsonium
symptoms, and increased risk and development of PD. Age-related degeneration of the
nigrostriatal system has been observed as indicated by loss of dopamine neurons in the
SN, decline in DA tissue and extracellular levels in SN and STR, and loss of
dopaminergic neuronal function. A better understanding of changes in the pro-survival
cellular signaling kinases (ERK1, 2, and 5), known to protect DA neurons against toxins,
in these dopaminergic regions will provide an insight into their mechanistic role in
dopamine neuronal survival.
In this work, a decline in ERK5 activation with age in the SN and STR
dopaminergic regions was observed. Higher expression of ERK5 was observed in these
regions during early postnatal day, which decline with postnatal development.
Concomitant expression of ERK1and ERK2 was low at early postnatal day, which
increased with postnatal development. When ERK5 signaling was blocked, it resulted
into early loss of DA neurons. These findings suggest the possibility that ERK5 signaling
is crucial for the basal dopamine neuronal survival during early postnatal development
and during aging. Secondly, it also suggests that a loss of ERK5 signaling in the
dopaminergic regions, SN and STR, may contribute to the normal age-related decline of
nigrostriatal dopaminergic function and possibly to the pathogenesis of age-related
neurodegenerative disorders such as Parkinson’s disease. It will be important to
investigate the ERK5 expression change in the aged and PD human brain samples, along
with conditionally knocking down ERK5 signaling in the dopaminergic system of rodents
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and measuring its outcomes in terms of motor deficits, DA neuronal physiology , and
function. It will be also important to elucidate the reasons for the age-related reduction in
ERK5 in these regions; whether they are associated with age-related alteration in
neurotrophic factors or reduction in receptor-mediated amplification or activation of
cellular signaling.
Compared to previous studies, neuroprotective mechanisms of GDNF and DNSP11 against 6-OHDA-induced toxicity were evaluated in the human dopaminergic
neuroblastoma SH-SY5Y cell line. Neurotrophic factor GDNF and its propeptide DNSP11 were able to activate pro-survival ERK1, 2, and 5 kinases. Infusion of DNSP-11 into
the STR resulted into modulation of ERK1, 2, and 5 signaling, along with TH protein
expression not only in the STR, but also in SN. Hence, as future direction, it will valuable
to evaluate whether DNSP-11 infusion into the STR leads to its retrograde signaling from
DA nerve terminal into the DA cell bodies in the SN. Effect of DNSP-11 on the
phosphorylation states of TH are still need to be studied, which would address increase in
DA levels in the STR and SN on DNSP-11 infusion. In order to elucidate distinct role of
ERK1, 2, and 5 in the dopaminergic system development conditional knockdown of
ERK1, 2, and 5 will be necessitated. Further, it will be important to determine whether
GDNF and DNSP-11 mediated protection of dopaminergic neurons against neurotoxinsinduced oxidative stress, in vivo or in vitro involve protective ERK5 signaling.
With the increase in aging population and increased risk of development of
neurodegenerative diseases, such as PD, it becomes important to understand the
alterations in cellular signaling pathways that are crucial for neuronal survival during
development and with aging. Understanding the modulation of cellular signaling
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pathways and molecular mechanisms involved in neuronal death with aging, such as DA
neuronal cell death in PD, will help to design therapeutic treatments to activate these
protective cellular signaling, thereby preventing the loss of neuron. This dissertation
addresses the importance of MAPK kinase signaling proteins, ERK1, 2, and 5 for the DA
neuronal survival and activation of these kinases by promising neurotrophic factor,
GDNF, and its pro-peptide molecule, DNSP-11.
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